Updated on 2023/08/03

写真a

 
MIZUNO Mika
 
Organization
University Hospital, Medical and Dental Sciences Area University Hospital Clinical Center Women's Medical Center Lecturer
Title
Lecturer
External link

Degree

  • 医学博士 ( 2010.4   名古屋大学 )

Research Interests

  • 卵巣癌

  • 子宮体癌

  • 子宮頸癌

  • 腫瘍

  • 産婦人科

Research Areas

  • Life Science / Human pathology  / 婦人科腫瘍

  • Life Science / Obstetrics and gynecology

Research History

  • Kagoshima University   Medical and Dental Hospital, Medical and Dental Sciences Area Medical and Dental Hospital Clinical Center Women's Medical Center   Senior Assistant Professor

    2020.4

Professional Memberships

  • 日本がん治療学会

    1996.3

 

Papers

  • Togami S, Fukuda M, Mizuno M, Yanazume S, Kobayashi H .  Efficacy and prognosis of robotic surgery with sentinel node navigation surgery in endometrial cancer. .  Journal of gynecologic oncology   2023.5Efficacy and prognosis of robotic surgery with sentinel node navigation surgery in endometrial cancer.

    　More details

    Language：English  

    DOI： 10.3802/jgo.2023.34.e68

    PubMed

  • Yanazume S., Iwakiri K., Kobayashi Y., Kitazono I., Akahane T., Mizuno M., Togami S., Tanimoto A., Kobayashi H. .  Cytopathological features associated with POLE mutation in endometrial cancer .  Cytopathology34 ( 3 ) 211 - 218   2023.5

    　More details

    Language：Japanese   Publisher：Cytopathology  

    Objective: For patients with endometrial cancer, the POLE (polymerase epsilon) mutation (POLEmut)-subtype, one of four molecular-analysis-based categories in the Cancer Genome Atlas (TCGA), has the best prognosis. The following histological characteristics are typically observed in endometroid carcinoma cases with the POLEmut-subtype: (1) the presence of tumour giant cells, (2) numerous tumour-infiltrating lymphocytes (TILs) and/or peri-tumoral lymphocytes, and (3) a high grade. However, in the context of cytology, the morphological characteristics of this subtype remain unknown. Methods: DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues was subjected to next-generation sequencing analysis and categorised according to the TCGA classifications. Genomic mutation, tumour mutation burden (TMB), and microsatellite instability were also assessed. Cytological specimens of resected uteri obtained using the Papanicolaou method were histologically separated into three types. Results: Seven out of 112 patients (6%) with endometrial cancer were diagnosed with the POLEmut-subtype between January 2019 and August 2021. Tumour giant cells were observed in three cases (43%) on histology and cytology. TIL and/or peritumoral lymphocytes with inflammatory cells were detected in five cases (71%) on histology and three cases (43%) on cytology. Cases in which these three characteristics were observed on both cytology and histology may have belonged to the POLEmut-subtype. There were no cases in which these characteristics were absent on histology but present on cytology. TMB tended to be higher in cases when the three characteristics were observed in both cytological and histological findings. Conclusions: Preoperative endometrial cytology highlighted the characteristics of the POLEmut-subtype in the histological analysis of resected uterine specimens and has the potential to play an important role in treatment decisions.

    DOI： 10.1111/cyt.13215

    Scopus

    PubMed

  • Mizuno M., Ito K., Nakai H., Kato H., Kamiura S., Ushijima K., Nagao S., Takano H., Okadome M., Takekuma M., Tokunaga H., Nagase S., Aoki D., Coleman R.L., Nishimura Y., Ratajczak C.K., Hashiba H., Xiong H., Katsumata N., Enomoto T., Okamoto A. .  Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial .  International Journal of Clinical Oncology28 ( 1 ) 163 - 174   2023.1

    　More details

    Language：Japanese   Publisher：International Journal of Clinical Oncology  

    Background: The phase 3 VELIA trial evaluated veliparib with carboplatin/paclitaxel and as maintenance in patients with high-grade serous ovarian carcinoma. Methods: Patients with previously untreated stage III–IV high-grade serous ovarian carcinoma were randomized 1:1:1 to control (placebo with carboplatin/paclitaxel and placebo maintenance), veliparib-combination-only (veliparib with carboplatin/paclitaxel and placebo maintenance), or veliparib-throughout (veliparib with carboplatin/paclitaxel and veliparib maintenance). Randomization stratification factors included geographic region (Japan versus North America or rest of the world). Primary end point was investigator-assessed median progression-free survival. Efficacy, safety, and pharmacokinetics were evaluated in a subgroup of Japanese patients. Results: Seventy-eight Japanese patients were randomized to control (n = 23), veliparib-combination-only (n = 30), and veliparib-throughout (n = 25) arms. In the Japanese subgroup, median progression-free survival for veliparib-throughout versus control was 27.4 and 19.1 months (hazard ratio, 0.46; 95% confidence interval, 0.18–1.16; p = 0.1 [not significant]). In the veliparib-throughout arm, grade 3/4 leukopenia, neutropenia, and thrombocytopenia rates were higher for Japanese (32%/88%/32%) versus non-Japanese (17%/56%/28%) patients. Grade 3/4 anemia rates were higher in non-Japanese (65%) versus Japanese (48%) patients. Early introduction of olanzapine during veliparib monotherapy maintenance phase may help prevent premature discontinuation of veliparib, via its potent antiemetic efficacy. Conclusions: Median progression-free survival was numerically longer in Japanese patients in the veliparib-throughout versus control arm, consistent with results in the overall study population. Pharmacokinetics were comparable between Japanese and non-Japanese patients. Data for the subgroup of Japanese patients were not powered to show statistical significance but to guide further investigation.

    DOI： 10.1007/s10147-022-02258-x

    Scopus

    PubMed

  • Mizuno Mika, Ito Kimihiko, Nakai Hidekatsu, Kato Hidenori, Kamiura Shoji, Ushijima Kimio, Nagao Shoji, Takano Hirokuni, Okadome Masao, Takekuma Munetaka, Tokunaga Hideki, Nagase Satoru, Aoki Daisuke, Coleman Robert L., Nishimura Yasuko, Ratajczak Christine K., Hashiba Hideyuki, Xiong Hao, Katsumata Noriyuki, Enomoto Takayuki, Okamoto Aikou .  Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial(タイトル和訳中) .  International Journal of Clinical Oncology28 ( 1 ) 163 - 174   2023.1Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial(タイトル和訳中)

    　More details

    Language：English   Publisher：シュプリンガー・ジャパン(株)  

    未治療のステージIII～IVの高悪性度漿液性卵巣癌患者を対象に、PARP阻害剤であるベリパリブとカルボプラチン/パクリタキセルを併用し、維持療法としてベリパリブを継続投与した無作為化国際第3相試験(VELIA/GOG-3005試験)が実施された。本研究では、当該試験における日本人サブグループの安全性、有効性、薬物動態を解析した。日本人卵巣癌患者78例を対照群23例(年齢44～75歳)、ベリパリブ併用群30例、ベリパリブスルーアウト(併用療法および維持療法)群25例(年齢43～75歳)に無作為に割り付けた。ベリパリブスルーアウト群と対照群の無増悪生存期間中央値は27.4ヵ月と19.1ヵ月であった(ハザード比0.46、95%CI 0.18～1.16、p=0.1)。ベリパリブスルーアウト群では、グレード3/4の白血球減少、好中球減少、血小板減少の発生率は、日本人患者(32%/88%/32%)で非日本人患者(17%/56%/28%)よりも高くなった。グレード3/4の貧血の割合は、日本人患者(48%)よりも非日本人患者(65%)で高かった。ベリパリブ維持療法の初日に制吐剤オランザピンを投与された患者6例では吐き気や嘔吐によるベリパリブの早期中止はなかった。以上より、日本人患者において、無増悪生存期間中央値はベリパリブスルーアウト群で対照群よりも数値的に長く、試験集団全体の結果と一致した。

  • Togami S., Tokudome A., Fukuda M., Mizuno M., Yanazume S., Kobayashi H. .  Validation of single-photon emission computed tomography with computed tomography and lymphoscintigraphy for sentinel lymph node identification in cervical cancer .  International Journal of Gynecology and Obstetrics   2023

    　More details

    Language：Japanese   Publisher：International Journal of Gynecology and Obstetrics  

    Objective: To compare single-photon emission computed tomography with computed tomography (SPECT/CT) and lymphoscintigraphy (LSG) for the detection of sentinel lymph nodes (SLNs) in patients with early-stage cervical cancer. Methods: This hospital-based, single-center, retrospective study included 128 patients with cervical cancer (aged >18 years) treated between 2014 and 2022. Injection of 99 m Technetium-labeled phytate into the uterine cervix was used to detect pelvic SLNs. SNL identification rates and locations were analyzed for preoperative LSG and SPECT/CT. Results: Median age and body mass index of patients were 40 years (range, 20–78 years) and 21.7 kg/m2 (range, 16–40 kg/m2), respectively. There was no significant difference in overall identification rates (identification of at least one SLN) of SLNs between SPECT/CT (91%) and LSG (88%). There was no significant difference in bilateral SLN identification rates between SPECT/CT (66%) and LSG (65%). A total of 219 pelvic SLNs (110 right and 109 left hemipelvis) were identified by SPECT/CT; the most frequent locations were the obturator (122 SLNs, 56%) and external iliac (67 SLNs, 30%). Conclusion: SPECT/CT and LSG showed high SLN identification rates in patients with cervical cancer, and there was no significant difference in overall or bilateral SLN identification rates between the two techniques.

    DOI： 10.1002/ijgo.14917

    Scopus

    PubMed

  • Otsuka S, Yanazume S, Mizuno M, Togami S, Kobayashi H .  Metastatic Leiomyoma Following Menopause: A Case Report and Review of Literature. .  Cureus14 ( 11 ) e31549   2022.11Metastatic Leiomyoma Following Menopause: A Case Report and Review of Literature.

    　More details

    Language：English  

    DOI： 10.7759/cureus.31549

    PubMed

  • 水野 美香, 川原 裕史, 福田 美香, 小林 裕介, 牛若 昂志, 小林 裕明 .  卵巣漿液性嚢胞腺腫に合併した微小な高悪性度漿液性癌と漿液性卵管上皮内病変の1例 .  鹿児島産科婦人科学会雑誌30   71 - 75   2022.3卵巣漿液性嚢胞腺腫に合併した微小な高悪性度漿液性癌と漿液性卵管上皮内病変の1例

    　More details

    Language：Japanese   Publisher：鹿児島産科婦人科学会  

    症例は68歳女性で、約3年前に肺癌IVA期と診断され、肺癌治療前のCT画像で右卵巣にも多房性卵巣嚢腫が指摘されていた。その後、右卵巣が徐々に増大しており当科に紹介となった。腹腔鏡下両側付属器切除術が施行され、右卵巣腫瘍は薄白色、多房性であり、周囲との癒着を認めなかった。永久標本病理学診断では、右卵巣は多房性嚢胞性腫瘍で大半はserous cystadenomaであるが、一部乳頭状を呈する上皮を認めた。免疫組織化学染色所見とあわせて、右卵巣腫瘍はごく一部にHigh-grade serous carcinomaを伴うserous cystadenomaであると判断し、右卵管はserous tubal intraepithelial lesionと診断を下した。術後1年7ヵ月経過した現在、腹水貯留はみられず、腫瘍マーカーとして血清CA125値の上昇もみられず、CT画像においても肺癌の増悪および卵巣癌の明らかな再発を認めていない。

  • 牛若 昂志, 戸上 真一, 瀧 つばき, 丸山 友美, 東 友梨子, 水野 美香, 小林 裕明 .  ロボット支援傍大動脈リンパ節郭清時に遭遇した右腎動脈の破格1例 .  鹿児島産科婦人科学会雑誌30   65 - 70   2022.3ロボット支援傍大動脈リンパ節郭清時に遭遇した右腎動脈の破格1例

    　More details

    Language：Japanese   Publisher：鹿児島産科婦人科学会  

    症例は28歳女性で、月経不順と挙児希望を主訴に前医を受診した。経腟超音波断層法で子宮体下部に3cm大高輝度エコー領域を指摘され、組織診で類内膜癌Grade 1を認めたため当科紹介となった。傍大動脈リンパ節郭清を伴う子宮体癌手術の方針とし、当科で行っている私費臨床試験「ロボット支援子宮体癌根治術(子宮・付属器摘出+骨盤傍大動脈リンパ節郭清±大網・虫垂切除)の確立」への参加を希望され、ロボット支援での根治手術を施行した。傍大動脈リンパ節郭清時に大動脈分岐から1cmほど頭側の高さで腹部大動脈から直接右側へ出る血管を認め、同様に下腸間膜動脈から1cm尾側にも腹部大動脈から右側へ出る血管を認めた。右腎動脈の破格を疑い術中に再度造影CTを確認したところ、2本の血管は右腎に流入しており右腎動脈の破格であることが判明した。現在術後半年が経過しているが再発なく経過している。

  • Togami Shinichi, Ushiwaka Takashi, Fukuda Mika, Mizuno Mika, Yanazume Shintaro, Kamio Masaki, Kobayashi Hiroaki .  Comparison of radio-isotope method with 99m technetium and near-infrared fluorescent imaging with indocyanine green for sentinel lymph node detection in endometrial cancer(和訳中) .  Japanese Journal of Clinical Oncology52 ( 1 ) 24 - 28   2022.1Comparison of radio-isotope method with 99m technetium and near-infrared fluorescent imaging with indocyanine green for sentinel lymph node detection in endometrial cancer(和訳中)

    　More details

    Language：English   Publisher：Oxford University Press  

    子宮摘出術と両側卵管卵巣摘出術を受けた子宮内膜癌(EC)患者において、99mテクネシウム(99mTc)による方法とインドシアニングリーン(ICG)を用いた近赤外蛍光イメージングによる骨盤内センチネルリンパ節の検出率を後方視的に検討した。EC患者122例(年齢28～81歳)を対象とした。全例におけるセンチネルリンパ節検出率(1個以上のセンチネルリンパ節の検出)は、99mTc(95.9%、117/122例)とICG(94.3%、115/122例)で有意差はなかった。両側のセンチネルリンパ節検出率では、99mTc(87.7%、107/122例)とICG(79.5%、97/122例)の間で有意差はなかった。片側骨盤リンパ節あたり2個以上のセンチネルリンパ節は、右骨盤側で99mTcとICGによりそれぞれ12.3%(15/122例)と27%(33/122例)、左骨盤側で99mTcとICGによりそれぞれ11.5%(14/122例)と32.8%(40/122例)で確認された。ICGでは、左右いずれの骨盤リンパ節においても、2つ以上のセンチネルリンパ節が有意に多かった(p<0.0001)。総センチネルリンパ節数の平均値は、99mTc(2.2個)とICG(2.5個)で有意差があった(p=0.028)。以上より、ICGを用いた近赤外蛍光イメージングはセンチネルリンパ節の同定に有用であった。

  • Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I .  Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). .  Journal of clinical oncology : official journal of the American Society of Clinical Oncology39 ( 33 ) 3671 - 3681   2021.11Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).

    　More details

    Language：English  

    DOI： 10.1200/JCO.21.00334

    PubMed

  • Togami S, Ushiwaka T, Fukuda M, Mizuno M, Yanazume S, Kamio M, Kobayashi H .  Comparison of radio-isotope method with 99m technetium and near-infrared fluorescent imaging with indocyanine green for sentinel lymph node detection in endometrial cancer. .  Japanese journal of clinical oncology52 ( 1 ) 24 - 28   2021.10

    　More details

    Language：English   Publisher：Japanese Journal of Clinical Oncology  

    Background: We aimed to compare the detection rate of pelvic sentinel lymph node between the radio-isotope with 99m technetium (99mTc)-labeled phytate and near-infrared fluorescent imaging with indocyanine green in patients with endometrial cancer. Methods: This study included 122 patients who had undergone sentinel lymph node mapping using 99mTc and indocyanine green. In the radio-isotope method, sentinel lymph nodes were detected using uterine cervix 99mTc injections the day before surgery. Following injection, the number and locations of the sentinel lymph nodes were evaluated by lymphoscintigraphy. In addition, indocyanine green was injected into the cervix immediately before surgery. Results: The overall pelvic sentinel lymph node detection rate (at least one pelvic sentinel lymph node detected) was not significantly different between 99mTc (95.9% [117/122]) and indocyanine green (94.3% [115/122]). Similarly, the bilateral sentinel lymph node detection rate was not significantly different between 99mTc (87.7% [107/122]) and indocyanine green (79.5% [97/122]). More than two sentinel lymph nodes per unilateral pelvic lymph node were found in 12.3% (15/122) and 27% (33/122) of cases with 99mTc and indocyanine green, respectively, in the right pelvic side, and 11.5% (14/122) and 32.8% (40/122) of cases with 99mTc and indocyanine green, respectively, in the left pelvic side. indocyanine green showed that there were significantly more than two sentinel lymph nodes in either the left or right pelvic sentinel lymph nodes (P < 0.0001). There was a significant difference in the mean number of total pelvic sentinel lymph nodes between 99mTc (2.2) and indocyanine green (2.5) (P = 0.028) methods. Conclusion: Although indocyanine green is useful for sentinel lymph node identification, we believe it is better to use it in combination with 99mTc until the surgeon is accustomed to it.

    DOI： 10.1093/jjco/hyab172

    Scopus

    PubMed

  • Kawamura M, Koide Y, Murai T, Ishihara S, Takase Y, Murao T, Okazaki D, Yamaguchi T, Uchiyama K, Itoh Y, Kodaira T, Shibamoto Y, Mizuno M, Kikkawa F, Naganawa S .  The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments. .  BMC cancer21 ( 1 ) 1046   2021.9The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments.

    　More details

    Language：English  

    DOI： 10.1186/s12885-021-08772-x

    PubMed

  • 神尾 真樹, 牛若 昂志, 永野 大河, 大塚 祥子, 萬浮 帆波, 内田 那津子, 福田 美香, 水野 美香, 小林 裕明 .  卵巣腫瘍における腫瘍マーカーHE4の有用性 .  鹿児島産科婦人科学会雑誌29   21 - 27   2021.3卵巣腫瘍における腫瘍マーカーHE4の有用性

    　More details

    Language：Japanese   Publisher：鹿児島産科婦人科学会  

    卵巣腫瘍における新規腫瘍マーカーHE4(human epididymis protein 4)の有用性について検討した。原発性上皮性卵巣癌81例における治療開始前の腫瘍マーカーについて、単独の陽性率はCA125 81.5%、CA19-9 37.0%、CEA 9.9%であったが、これらの組み合わせによる陽性率は85.2%であった。組織型別では明細胞癌と粘液性癌の陽性率は60%程度であり、進行期別では進行とともに陽性率が上昇し、III期とIV期の陽性率は100%であった。HE4は感度が低いものの特異度は高く、最も効果的に悪性腫瘍を判定できる組み合わせの検討では、CA125、HE4、CEAが感度・特異度のバランスが良い組み合わせであった(感度94.1%・特異度75.0%)。今回、HE4やROMA指数の有用性は示されなかったが、CA125の低い特異性を補う可能性が示唆された。

  • Mizuno M. .  Efficacy of 5-aminolevulinic acid and LED photodynamic therapy in cervical intraepithelial neoplasia: A clinical trial .  Photodiagnosis and Photodynamic Therapy32   102004   2020.12

    　More details

    Publisher：Photodiagnosis and Photodynamic Therapy  

    DOI： 10.1016/j.pdpdt.2020.102004

    Scopus

    PubMed

  • Takekuma M. .  Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy .  BMC Cancer20 ( 1 ) 1169   2020.12

    　More details

    Publisher：BMC Cancer  

    DOI： 10.1186/s12885-020-07672-w

    Scopus

    PubMed

  • 水野 美香 .  【産婦人科領域におけるレーザー治療】子宮頸部上皮内腫瘍に対する5-aminolevulinic acidを用いた光線力学的療法 .  日本レーザー医学会誌40 ( 4 ) 375 - 380   2020.1【産婦人科領域におけるレーザー治療】子宮頸部上皮内腫瘍に対する5-aminolevulinic acidを用いた光線力学的療法

    　More details

    Publisher：(NPO)日本レーザー医学会  

    子宮頸部上皮内腫瘍は子宮頸癌の前駆状態であり,稀な疾患ではない.標準治療は,外科的切除であるが,この方法は早産率を有意に増加させることが報告されている.光線力学的療法(photodynamic therapy:PDT)は,子宮頸部上皮内癌に対しての低侵襲性治療である.従来法PDTは良好な治療成績が報告されているが,合併症である光線過敏症の懸念や,長期入院が必要なことから,普及率は低い.5-アミノレブリン酸は,アミノ酸の一種であり,増感作用を持つポルフィリン類の前駆物質である.我々は,子宮頸部上皮内腫瘍に対して,5-アミノレブリン酸とLED光源を用いたPDTの臨床試験を行った.(著者抄録)

  • Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA .  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. .  The New England journal of medicine381 ( 25 ) 2403 - 2415   2019.12Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    　More details

  • Nomura H, Aoki D, Susumu N, Mizuno M, Nakai H, Arai M, Nishio S, Tokunaga H, Nakanishi T, Watanabe Y, Yaegashi N, Yokoyama Y, Takehara K .  Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial. .  Gynecologic oncology155 ( 3 ) 413 - 419   2019.12Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial.

    　More details

  • Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, Tokunaga H, Matoda M, Nakanishi T, Watanabe Y, Takahashi F, Saito T, Yaegashi N, Japanese Gynecologic Oncology Group. .  Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. .  JAMA oncology5 ( 6 ) 833 - 840   2019.6Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.

    　More details

  • Kajiyama H, Suzuki S, Utsumi F, Nishino K, Niimi K, Mizuno M, Yoshikawa N, Kawai M, Oguchi H, Mizuno K, Yamamuro O, Shibata K, Nagasaka T, Kikkawa F .  Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database. .  Nagoya journal of medical science81 ( 2 ) 193 - 198   2019.5Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database.

    　More details

  • Kajiyama Hiroaki, Suzuki Shiro, Utsumi Fumi, Nishino Kimihiro, Niimi Kaoru, Mizuno Mika, Yoshikawa Nobuhisa, Kawai Michiyasu, Oguchi Hidenori, Mizuno Kimio, Yamamuro Osamu, Shibata Kiyosumi, Nagasaka Tetsuro, Kikkawa Fumitaka .  転移性卵巣癌の疫学的概観　TOTSGデータベースの長期経験(Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database) .  Nagoya Journal of Medical Science81 ( 2 ) 193 - 198   2019.5転移性卵巣癌の疫学的概観　TOTSGデータベースの長期経験(Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database)

    　More details

    Publisher：名古屋大学医学部  

    東海卵巣腫瘍研究会(TOTSG)のデータベースを用いて、1986〜2015年の期間における悪性卵巣腫瘍患者4284例を調査した。未分類の組織型、子宮由来の転移性卵巣腫瘍、データ不十分の患者126例は除外した。さらに境界域の悪性腫瘍患者680例を除外し、悪性卵巣癌患者3478例を抽出した。そのうち、残存腫瘍の情報不十分の7例は除外した。組織学的スライドは中央病理レビューシステムにて婦人科病理医が評価した。全体で患者の84.3%(2932例)が卵巣上皮癌であった。胚細胞腫瘍患者の割合は6.8%(238例)、性索間質性腫瘍患者の割合は3.3%(115例)であった。4.1%(143例)が転移性卵巣癌(MOC)であった。MOC患者の年齢中央値は54歳(29〜82歳)であった。原発癌で最も多かったのは大腸癌(43%)で、次いで胃癌(29%)が多く、虫垂癌は8%、乳癌は6%、膵癌は4%であった。

  • Minlikeeva AN, Cannioto R, Jensen A, Kjaer SK, Jordan SJ, Diergaarde B, Szender JB, Odunsi K, Almohanna H, Mayor P, Starbuck K, Zsiros E, Bandera EV, Cramer DW, Doherty JA, DeFazio A, Australian Ovarian Cancer Study Group., Edwards R, Goode EL, Goodman MT, Høgdall E, Matsuo K, Mizuno M, Nagle CM, Ness RB, Paddock LE, Pearce CL, Risch HA, Rossing MA, Terry KL, Wu AH, Modugno F, Webb PM, Moysich KB, Ovarian Cancer Association Consortium. .  Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. .  Cancer causes & control : CCC30 ( 5 ) 537 - 547   2019.5Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium.

    　More details

  • Lawrenson K, Song F, Hazelett DJ, Kar SP, Tyrer J, Phelan CM, Corona RI, Rodríguez-Malavé NI, Seo JH, Adler E, Coetzee SG, Segato F, Fonseca MAS, Amos CI, Carney ME, Chenevix-Trench G, Choi J, Doherty JA, Jia W, Jin GJ, Kim BG, Le ND, Lee J, Li L, Lim BK, Adenan NA, Mizuno M, Park B, Pearce CL, Shan K, Shi Y, Shu XO, Sieh W, Australian Ovarian Cancer Study Group., Thompson PJ, Wilkens LR, Wei Q, Woo YL, Yan L, Karlan BY, Freedman ML, Noushmehr H, Goode EL, Berchuck A, Sellers TA, Teo SH, Zheng W, Matsuo K, Park S, Chen K, Pharoah PDP, Gayther SA, Goodman MT .  Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. .  Gynecologic oncology153 ( 2 ) 343 - 355   2019.5Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.

    　More details

  • Inoue S, Ito H, Hosono S, Hori M, Matsuda T, Mizuno M, Kato K, Matsuo K .  Net Survival of Elderly Patients with Gynecological Cancer Aged Over 75 Years in 2006-2008 .  Asian Pacific journal of cancer prevention : APJCP20 ( 2 ) 437 - 442   2019.2Net Survival of Elderly Patients with Gynecological Cancer Aged Over 75 Years in 2006-2008

    　More details

  • Takeuchi F, Kukimoto I, Li Z, Li S, Li N, Hu Z, Takahashi A, Inoue S, Yokoi S, Chen J, Hang D, Kuroda M, Matsuda F, Mizuno M, Mori S, Wu P, Tanaka N, Matsuo K, Kamatani Y, Kubo M, Ma D, Shi Y .  Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection. .  Human molecular genetics28 ( 2 ) 341 - 348   2019.1Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection.

    　More details

  • Shimokawa M, Hayashi T, Kogawa T, Matsui R, Mizuno M, Kikkawa F, Saeki T, Aiba K, Tamura K .  Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy. .  Anticancer research39 ( 1 ) 225 - 230   2019.1Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy.

    　More details

  • Natsuo Tomita, Mika Mizuno, Chiyoko Makita, Shinji Kondo, Masahiko Mori, Jun Sakata, Hirofumi Tsubouchi, Kimiko Hirata, Hiroyuki Tachibana, Takeshi Kodaira .  Propensity Score Analysis of Radical Hysterectomy Versus Definitive Chemoradiation for FIGO Stage IIB Cervical Cancer .  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER28 ( 8 ) 1576 - 1583   2018.10Propensity Score Analysis of Radical Hysterectomy Versus Definitive Chemoradiation for FIGO Stage IIB Cervical Cancer

    　More details

    Publisher：BMJ PUBLISHING GROUP  

    Objective: The aim of this study was to compare the outcomes and toxicities of radical hysterectomy (RH) and definitive chemoradiation (CRT) for International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer.Materials and Methods: A retrospective analysis was performed on FIGO stage IIB patients who underwent RH with adjuvant radiotherapy (surgery group) or intended to receive CRT (CRT group). The distributions of disease-free survival (DFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Propensity score matching (PSM) was performed for the 2 groups based on age, tumor diameter, histological type, and pelvic node metastasis in pretreatment imaging tests.Results: Median follow-up times were 58 months in the surgery group (n = 75) and 55 months in the CRT group (n = 65). Propensity score matching identified 37 patients with similar characteristics from each group. Significant differences were observed in the ratio of the chemotherapy combination between the surgery and CRT groups before (47% vs 98%) and after PSM (51% vs 100%). Five-year DFS rates were slightly higher in the surgery group than in the CRT group before PSM (69% vs 58%, P = 0.30) but were similar after PSM (76% vs 82%, P = 0.36). Five-year OS rates were similar between the surgery and CRT groups before (70% vs 75%, P = 0.59) and after PSM (78% vs 77%, P = 0.97). The results of multivariate analyses also showed that neither DFS nor OS was associated with the treatment modalities regardless of PSM. The incidence of late toxicities grade 2 or greater was similar between the surgery and CRT groups before (17% vs 23%, P = 0.31) and after PSM (19% vs 24%, P = 0.78).Conclusions: The results of this study suggest that RH with adjuvant radiotherapy and definitive CRT are equivalent treatment options for patients with FIGO stage IIB cancer. However, prospective larger studies are needed to confirm this.

    DOI： 10.1097/IGC.0000000000001336

    Web of Science

    PubMed

  • Natsuo Tomita, Mika Mizuno, Shinji Kondo, Masahiko Mori, Sho Takeshita, Jun Sakata, Hirofumi Tsubouchi, Takeshi Kodaira .  Role of Extensive Lymphadenectomy in Early-Stage Cervical Cancer Patients With Radical Hysterectomy Followed by Adjuvant Radiotherapy .  INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER28 ( 6 ) 1211 - 1217   2018.7Role of Extensive Lymphadenectomy in Early-Stage Cervical Cancer Patients With Radical Hysterectomy Followed by Adjuvant Radiotherapy

    　More details

    Publisher：BMJ PUBLISHING GROUP  

    Objectives The objective of this study was to assess the effect of extensive lymphadenectomy on survival of early-stage cervical cancer patients with radical hysterectomy followed by adjuvant radiotherapy (RT).Materials and Methods A retrospective analysis was performed on early-stage patients with high-risk factors who received radical hysterectomy with lymphadenectomy followed by adjuvant RT. All patients were divided into the less than or equal to 40 dissected pelvic lymph nodes (DPLN 40) and greater than 40 dissected pelvic lymph nodes (DPLN >40) groups to assess the effect of extensive lymphadenectomy. Distributions of disease-free survival (DFS) and overall survival (OS) were calculated by the Kaplan-Meier method. Significance of survival was assessed by the log-rank test. Cox proportional hazards models were applied to assess the effects of the factors on survival by univariate and multivariate analyses.Results After a median follow-up of 76 months for a total of 178 patients, 5-year DFS of the DPLN >40 group was significantly higher than that of the DPLN 40 group (86% vs 74%, P = 0.045). Five-year OS was comparable between the 2 groups (85% vs 78%, P = 0.49). The multivariate analysis showed that the DPLN 40 group was at a significantly higher risk of recurrence (hazard ratio, 2.3; 95% confidence interval (CI), 1.1-4.8; P = 0.020), whereas OS was not affected by the DPLN group (P = 0.26). Positive pelvic lymph node, parametrial invasion, histological type, and the absence of RT-combined chemotherapy remained significant prognostic factors for lower DFS and OS by the multivariate analysis. Adjusted hazard ratio of DPLN 40 for DFS was 1.2 (95% CI, 0.11-12; P = 0.91) in patients with negative pelvic lymph node (PLN) whereas it was 2.6 (95% CI, 1.1-5.8; P = 0.024) in patients with positive PLN.Conclusions These results suggest that more extensive lymphadenectomy significantly improve the outcomes of patients with positive PLN even followed by adjuvant RT.

    DOI： 10.1097/IGC.0000000000001279

    Web of Science

    PubMed

  • Maki Matoda, Nobuhiro Takeshima, Hirofumi Michimae, Takashi Iwata, Harushige Yokota, Yutaka Torii, Yorito Yamamoto, Kazuhiro Takehara, Shin Nishio, Hirokuni Takano, Mika Mizuno, Yoshiyuki Takahashi, Yuji Takei, Tetsuya Hasegawa, Mikio Mikami, Takayuki Enomoto, Daisuke Aoki, Toru Sugiyama .  Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067) .  Gynecologic Oncology149 ( 3 ) 513 - 519   2018.6Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067)

    　More details

    Publisher：Academic Press Inc.  

    Objective: This multicenter phase II Japanese Gynecologic Oncology Group study (JGOG1067) was designed to evaluate the efficacy and safety of postoperative chemotherapy in patients with node-positive cervical cancer. Methods: Patients with stage IB–IIA squamous cervical cancer who underwent radical hysterectomy and were confirmed to have pelvic lymph node metastasis were eligible for this study. The patients postoperatively received irinotecan (CPT-11
    60 mg/m2 intravenously on days 1 and 8) and nedaplatin (NDP
    80 mg/m2 intravenously on day 1). Chemotherapy administration commenced within 6 weeks after surgery and was repeated every 28 days for up to 5 cycles. The primary endpoint of this study was the 2-year recurrence-free survival (RFS) rate. The secondary endpoints were the 5-year overall survival (OS) rate, 5-year RFS rate, and adverse events such as complications of chemotherapy and lower-limb edema. Results: Sixty-two patients were analyzed according to our protocol, among whom 55 (88.7%) completed 5 cycles of scheduled treatment. The median follow-up period was 66.1 months (range, 16.8–96.6 months). The 2-year and 5-year RFS rates were 87.1% (95% confidence interval [CI]: 75.9–99.3) and 77.2% (95% CI: 64.5–85.8), respectively. Fourteen patients (22.5%) experienced recurrence during the follow-up period, 8 of whom died of the disease. The 5-year OS rate in this study was 86.5% (95% CI: 74.8–93.0). Only 9.7% of the patients experienced lymphedema in their legs. Conclusion: Postoperative chemotherapy without radiotherapy was found to be very effective in high-risk patients with node-positive cervical cancer.

    DOI： 10.1016/j.ygyno.2018.04.009

    Scopus

    PubMed

  • Toshiya Teshigawara, Mika Mizuno, Takuya Ishii, Yuya Kitajima, Fumi Utsumi, Jun Sakata, Hiroaki Kajiyama, Kiyosumi Shibata, Masahiro Ishizuka, Fumitaka Kikkawa .  Novel potential photodynamic therapy strategy using 5-Aminolevulinic acid for ovarian clear-cell carcinoma .  Photodiagnosis and Photodynamic Therapy21   121 - 127   2018.3Novel potential photodynamic therapy strategy using 5-Aminolevulinic acid for ovarian clear-cell carcinoma

    　More details

    Publisher：Elsevier B.V.  

    Background Photodynamic therapy (PDT) is known as a minimally invasive treatment for cancer. 5-Aminolevulinic acid (ALA) is a precursor of the photosensitizing agent protoporphyrin IX (PpIX). Patients with ovarian clear-cell carcinoma (CCC) have poorer prognoses than those of patients with other histological CCC types. We evaluated the efficacy of ALA-PDT on CCC cells in vitro. Methods We used seven human CCC cell lines to measure the cytotoxicity of ALA-PDT. PpIX production in cancer cells was measured using a micro-plate reader. Quantitative real-time PCR was performed to assess the mRNA levels of genes involved in the accumulation of PpIX in cancer cells. Additionally, we measured the enhancement in cytotoxicity with the use of an ABCG2 inhibitor. Results We found that three cell lines were highly sensitive to ALA-PDT. In contrast, one cell line was resistant to ALA-PDT. The cytotoxicity of ALA-PDT varied among CCC cell lines. The IC50 values of ALA-PDT for the CCC cell lines had a wide range (30–882 μM). The cytotoxicity of ALA-PDT was correlated with the intracellular PpIX accumulation. The cell lines sensitive to ALA-PDT expressed PEPT1 (an ALA uptake transporter). The cell line resistant to ALA-PDT expressed ABCG2 (a PpIX export transporter). In the resistant cell line, a combination treatment with both ALA and an ABCG2 inhibitor resulted in the promotion of cytotoxic sensitivity. Conclusion The present study revealed the efficacy of ALA-PDT against CCC with chemoresistance in vitro.

    DOI： 10.1016/j.pdpdt.2017.11.013

    Scopus

    PubMed

  • Tomotaka Ugai, Linda E. Kelemen, Mika Mizuno, Jue-Sheng Ong, Penelope M. Webb, Georgia Chenevix-Trench, Kristine G. Wicklund, Jennifer Anne Doherty, Mary Anne Rossing, Pamela J. Thompson, Lynne R. Wilkens, Michael E. Carney, Marc T. Goodman, Joellen M. Schildkraut, Andrew Berchuck, Daniel W. Cramer, Kathryn L. Terry, Hui Cai, Xiao-Ou Shu, Yu-Tang Gao, Yong-Bing Xiang, David Van Den Berg, Malcom C Pike, Anna H. Wu, Celeste Leigh Pearce, Keitaro Matsuo, on behalf of the Australian Ovarian Cancer Study Group .  Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium .  Cancer Science109 ( 2 ) 435 - 445   2018.2Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium

    　More details

    Publisher：Blackwell Publishing Ltd  

    The aldehyde dehydrogenase 2 (ALDH2) polymorphism rs671 (Glu504Lys) causes ALDH2 inactivation and adverse acetaldehyde exposure among Asians, but little is known of the association between alcohol consumption and rs671 and ovarian cancer (OvCa) in Asians. We conducted a pooled analysis of Asian ancestry participants in the Ovarian Cancer Association Consortium. We included seven case-control studies and one cohort study comprising 460 invasive OvCa cases, 37 borderline mucinous OvCa and 1274 controls of Asian descent with information on recent alcohol consumption. Pooled odds ratios (OR) with 95% confidence intervals (CI) for OvCa risk associated with alcohol consumption, rs671 and their interaction were estimated using logistic regression models adjusted for potential confounders. No significant association was observed for daily alcohol intake with invasive OvCa (OR comparing any consumption to none = 0.83
    95% CI = 0.58-1.18) or with individual histotypes. A significant decreased risk was seen for carriers of one or both Lys alleles of rs671 for invasive mucinous OvCa (OR = 0.44
    95% CI = 0.20-0.97) and for invasive and borderline mucinous tumors combined (OR = 0.48
    95% CI = 0.26-0.89). No significant interaction was observed between alcohol consumption and rs671 genotypes. In conclusion, self-reported alcohol consumption at the quantities estimated was not associated with OvCa risk among Asians. Because the rs671 Lys allele causes ALDH2 inactivation leading to increased acetaldehyde exposure, the observed inverse genetic association with mucinous ovarian cancer is inferred to mean that alcohol intake may be a risk factor for this histotype. This association will require replication in a larger sample.

    DOI： 10.1111/cas.13470

    Scopus

    PubMed

  • Inoue Shusaku, Hosono Satoyo, Ito Hidemi, Oze Isao, Nishino Yoshikazu, Hattori Masakazu, Matsuda Tomohiro, Miyashiro Isao, Nakayama Tomio, Mizuno Mika, Matsuo Keitaro, Kato Kiyoko, Tanaka Hideo, Ito Yuri .  本邦における1993〜2000年から2001〜2006年迄の子宮体癌における5年相対生存率の改善(Improvement in 5-Year Relative Survival in Cancer of the Corpus Uteri From 1993-2000 to 2001-2006 in Japan) .  Journal of Epidemiology28 ( 1-2 ) 75 - 80   2018.2本邦における1993〜2000年から2001〜2006年迄の子宮体癌における5年相対生存率の改善(Improvement in 5-Year Relative Survival in Cancer of the Corpus Uteri From 1993-2000 to 2001-2006 in Japan)

    　More details

    Language：English   Publisher：日本疫学会  

    本邦における子宮体癌患者の生存率の変化を調べた。山形県、宮城県、福井県、新潟県、大阪府、長崎県の集団ベースのがん登録から1993〜2006年に診断された8562例のデータを得た。時期は第1期(1993〜2000年)および第2期(2001〜2006年)に分けた。年齢群、疾患の範囲、組織学的サブタイプに対する補正後の超過死亡モデルを用いて各期の相対生存率(RS)を算出し変化を評価した。全5年RSは第1期の77.7%から第2期の80.2%に向上した。超過ハザード比(EHR)は0.785であった。5年RSは55〜69歳群、全疾患範囲群、類内膜腺癌群において有意に向上したことが示された。特に類内膜腺癌群では、5年RSが84.5%から89.7%に上昇し、EHRは0.698(95%CI 0.560-0.870)であり、有意な改善を認めた。以上から、本邦において子宮体癌患者の全5年RSは1990年代から2000年代前半にかけて向上したことが示された。

  • Ugai Tomotaka, Kelemen Linda E., Mizuno Mika, Ong Jue-Sheng, Webb Penelope M., Chenevix-Trench Georgia, Wicklund Kristine G., Doherty Jennifer Anne, Rossing Mary Anne, Thompson Pamela J., Wilkens Lynne R., Carney Michael E., Goodman Marc T., Schildkraut Joellen M., Berchuck Andrew, Carmer Daniel W., Terry Kathryn L., Cai Hui, Shu Xiao-Ou, Gao Yu-Tang, Xiang Yong-Bing, Van Den Berg David, Pike Malcom C., Wu Anna H., Pearce Celeste Leigh, Matsuo Keitaro, the Australian Ovarian Cancer Study Group .  卵巣癌リスク、ALDH2遺伝子多型、飲酒　Ovarian Cancer Association Consortiumで得られたアジア人のデータ(Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium) .  Cancer Science109 ( 2 ) 435 - 445   2018.2卵巣癌リスク、ALDH2遺伝子多型、飲酒　Ovarian Cancer Association Consortiumで得られたアジア人のデータ(Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium)

    　More details

    Publisher：John Wiley & Sons Australia, Ltd  

    アジア人集団において、卵巣癌リスク、アルコール消費量、アルデヒドデヒドロゲナーゼ(ALDH)2のrs671(Glu504Lys)多型の3因子間にどのような関連性が存在するのか検討する目的で統合解析を施行した。Ovarian Cancer Association Consortiumにおける症例対照研究7件、コホート研究1件を組み入れ、アジア人系でかつ最近のアルコール消費量に関する情報が得られた参加者のうち、浸潤性卵巣癌に罹患した460例と粘液性境界悪性卵巣腫瘍の37例、および対照となる1274例を調査対象とした。交絡因子を調整したロジスティック回帰モデルによる統合オッズ比を推定したところ、1日あたりのアルコール摂取量と、浸潤性卵巣癌またはその個々の組織型との間に有意な関連性は示されなかった。rs671多型がLysであるアレルを少なくとも一つ持つ保因者では、浸潤性の粘液性卵巣癌のリスク(オッズ比0.44、95%信頼区間0.20〜0.97)や、浸潤性または境界悪性をあわせた粘液性卵巣腫瘍のリスク(オッズ比0.48,95%信頼区間0.26〜0.89)が有意に低下していた。アルコール消費量とrs671多型との間には有意な交互作用が認められなかった。アジア人集団において、自己申告に基づいたアルコール消費の推定量は卵巣癌リスクとは関連しないと考えられた。

  • Inoue S, Hosono S, Ito H, Oze I, Nishino Y, Hattori M, Matsuda T, Miyashiro I, Nakayama T, Mizuno M, Matsuo K, Kato K, Tanaka H, Ito Y, J-CANSIS Research Group .  Improvement in 5-Year Relative Survival in Cancer of the Corpus Uteri From 1993-2000 to 2001-2006 in Japan. .  Journal of epidemiology28 ( 2 ) 75 - 80   2018.2Improvement in 5-Year Relative Survival in Cancer of the Corpus Uteri From 1993-2000 to 2001-2006 in Japan.Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Medical circumstances in Japanese patients with cancer of the corpus uteri have greatly changed since the late 1990s, including the introduction of concomitant therapy with taxane and platinum. We evaluated changes in survival rates for this cancer following these advances by analyzing data from population-based cancer registries in Japan. METHODS: Data were available for 8562 cases of cancer of the corpus uteri from six prefectural cancer registries. We defined the two periods of 1993-2000 (1st period) and 2001-2006 (2nd period). Relative survival (RS) in each period was calculated to assess changes using an excess mortality model, with adjustment for age group (15-54, 55-69, and 70-99 years), extent of disease (localized, regional, and distant), and histological subtype. RESULTS: Overall 5-year RS improved from 77.7% in the 1st period to 80.2% in the 2nd period, with an excess hazard ratio (EHR) of 0.785 (95% confidence interval [CI], 0.705-0.873). Five-year RS significantly improved in the group aged 55-69 years, in all groups by extent of disease, and in the endometrioid adenocarcinoma group. In particular, 5-year RS significantly improved in patients with endometrioid adenocarcinoma, from 84.5% to 89.7%, with an EHR of 0.698 (95% CI, 0.560-0.870). CONCLUSION: Overall 5-year RS for cancer of the corpus uteri in Japan improved from the 1990s to early 2000s. These improvements might have been aided by the comprehensive medical development of management for this cancer, including the spread of concomitant therapy with taxane and platinum as a standard adjuvant chemotherapy in the early 2000s.

    DOI： 10.2188/jea.JE20170008

    PubMed

  • Satoshi Tamauchi, Hiroaki Kajiyama, Fumi Utsumi, Shiro Suzuki, Kaoru Niimi, Jun Sakata, Mika Mizuno, Kiyosumi Shibata, Fumitaka Kikkawa .  Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer .  Journal of Obstetrics and Gynaecology Research44 ( 1 ) 151 - 156   2018.1Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer

    　More details

    Publisher：Blackwell Publishing  

    Aim: Medroxyprogesterone acetate (MPA) is used to preserve fertility in patients with Grade 1 endometrial cancer without myometrial invasion (G1EA) and those with atypical endometrial hyperplasia (AEH). However, the efficacy of retreatment with MPA has not been sufficiently established for patients who experience recurrence but wish to retain their fertility. This study aimed to show the effectiveness of MPA treatment and retreatment for AEH and G1EA. Methods: A total of 39 patients received MPA treatment between 2005 and 2015, including nine with G1EA and 30 with AEH. The patients received high-dose (600 mg/day) MPA for 26 weeks. If a complete response was not achieved, MPA treatment was continued. After complete remission, if there was a recurrence, the patient was offered a choice of a hysterectomy or retreatment with MPA. The gynecologic and obstetric outcomes were retrospectively analyzed. Results: The median age was 34 years, and the median body mass index was 23.3 kg/m2. The median follow-up period was 52 months. Complete response rates for the initial treatment were 89% for G1EA and 93% for AEH. Recurrence occurred in 88% of patients with G1EA (7/8) and 50% of those with AEH (14/28). Seven patients with G1EA and 11 with AEH received MPA retreatment, and 100% and 92% of these achieved a complete response. During the study period, a total of 14 pregnancies were recorded with 10 live births. Conclusion: MPA can be effective for G1EA and AEH treatment even when they recur.

    DOI： 10.1111/jog.13473

    Scopus

    PubMed

  • Mitsuya Ishikawa, Takahiro Kasamatsu, Hitoshi Tsuda, Masaharu Fukunaga, Atsuhiko Sakamoto, Tsunehisa Kaku, Toru Nakanishi, Yoko Hasumi, Takashi Iwata, Tsukasa Baba, Takayoshi Nogawa, Wataru Kudaka, Hiroshi Kaneda, Shigemitsu Ono, Fumitaka Saito, Yoshimi Taniguchi, Satoshi Okada, Mika Mizuno, Takashi Onda, Nobuo Yaegashi .  Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study. .  Gynecologic oncology148 ( 1 ) 139 - 146   2018.1Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study.

    　More details

    PURPOSE: We aimed to determine appropriate treatment guidelines for patients with stages I-II high-grade neuroendocrine carcinomas (HGNEC) of the uterine cervix in a multicenter retrospective study. PATIENTS AND METHODS: We reviewed the clinicopathological features and prognoses of 93 patients with HGNEC of International Federation of Gynecology and Obstetrics (FIGO) stages I and II. All patients were diagnosed with HGNEC by central pathological review. RESULTS: The median overall survival (OS) and disease-free survival (DFS) were 111.3months and 47.4months, respectively. Eighty-eight patients underwent radical surgery, and five had definitive radiotherapy. The hazard ratio (HR) for death after definitive radiotherapy to death after radical surgery was 4.74 (95% confidence interval [CI], 1.01-15.90). Of the surgery group, 18 received neoadjuvant chemotherapy. Pathological prognostic factors and optimal adjuvant therapies were evaluated for the 70 patients. Forty-one patients received adjuvant chemotherapy with etoposide-platinum (EP) or irinotecan-platinum (CPT-P). Multivariate analyses identified the invasion of lymphovascular spaces as a significant prognostic factor for both OS and DFS. Pelvic lymph node metastasis was also a prognostic factor for DFS. Adjuvant chemotherapy with an EP or CPT-P regimen appeared to improve DFS (HR=0.27, 95% CI, 0.10-0.69). A trend toward improved OS was also observed, but was not statistically significant (HR=0.39, 95% CI, 0.15-1.01). CONCLUSION: Radical surgery followed by adjuvant chemotherapy with an EP or CPT-P regimen was optimal treatment for stages I and II HGNEC of the uterine cervix.

    DOI： 10.1016/j.ygyno.2017.10.027

    PubMed

  • Tamauchi Satoshi, Kajiyama Hiroaki, Utsumi Fumi, Suzuki Shiro, Niimi Kaoru, Sakata Jun, Mizuno Mika, Shibata Kiyosumi, Kikkawa Fumitaka .  子宮内膜異型増殖症および子宮内膜癌に対するメドロキシプロゲステロンアセテート治療および再治療の有効性(Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer) .  The Journal of Obstetrics and Gynaecology Research44 ( 1 ) 151 - 156   2018.1子宮内膜異型増殖症および子宮内膜癌に対するメドロキシプロゲステロンアセテート治療および再治療の有効性(Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer)

    　More details

    Publisher：John Wiley & Sons Australia, Ltd  

    メドロキシプロゲステロンアセテート(MPA)を投与して妊孕性温存治療を行った子宮内膜癌(EC)および子宮内膜異型増殖症(AEH)患者の転帰を解析し、原発性・再発ECおよびAEHに対するMPAの有効性を評価した。MPAを投与されたグレード1の子宮筋層浸潤を伴わないEC(G1EA)患者9例およびAEH患者30例の総計39例(年齢19〜45歳)に、高用量MPA 600mg/日を26週間投与し、完全寛解(CR)が得られない場合は治療を継続した。CR後に再発した場合には、子宮切除術またはMPAによる再治療の選択肢を用意した。これら患者の婦人科および産科的転帰を後ろ向きに解析した。その結果、中央値52ヵ月の経過観察期間中、初期治療の完全寛解率はG1EAで89%(8例)、AEH 93%(28例)であった。G1EA患者に対するMPA投与期間は、有意に長かった。CRを達成したG1EA患者の88%(7例)、AEH患者の50%(14例)が再発と診断され、それぞれ6例および12例がMPAによる再治療を行った。CR達成率はそれぞれ100%(6例)と92%(11例)であった。研究期間中、総計14妊娠で10例の生児出生が得られた。MPAはG1EAおよびAEH治療に有効で、再発時における再治療でも安全かつ有効であった。またMPA治療の継続は、患者妊孕性温存にも効果的であることが示唆された。

  • Hiroaki Kajiyama, Shiro Suzuki, Masato Yoshihara, Kimihiro Nishino, Nobuhisa Yoshikawa, Fumi Utsumi, Kaoru Niimi, Mika Mizuno, Michiyasu Kawai, Hidenori Oguchi, Kimio Mizuno, Osamu Yamamuro, Tetsuro Nagasaka, Kiyosumi Shibata, Fumitaka Kikkawa .  The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours .  Oncotarget9 ( 5 ) 6298 - 6307   2018The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours

    　More details

    Publisher：Impact Journals LLC  

    The objective of this study was to estimate the frequency of possible occult metastasis through long-term survival analyses in patients with clear cell carcinoma (CCC) who had undergone complete resection. During the period of 1990-2015, 799 patients with stage I-IV CCC were identified in the TOTSG database. Of these, a total of 528 patients without a residual tumor were enrolled in the study and classified into four groups: Group 1: FIGO stage IA-IB (N=104), Group 2: FIGO stage IC1 (N=170), Group 3: FIGO stage IC2/IC3 (N=98), and Group 4: FIGO stage II-III (no residual tumor: N=156). Cumulative incidences of recurrence (CIR) and death (CID) were examined. The median age was 54, ranging from 29-87. The 5-year CIR / CID of each group were as follows: Group 1 (7.3% / 3.8%), Group 2 (14.3% / 10.2%), Group 3 (37.7% / 18.4%), and Group 4 (46.5% / 33.8%), respectively (P &lt
    0.0001 (recurrence) / P &lt
    0.0001 (death)). Furthermore, confining analysis to relapsed patients, 1-, 2-, and 3-year CID after recurrence were 41.5, 60.9, and 73.9, respectively. Confining analyses to patients with sufficient information about adjuvant chemotherapy, the 5-year CIR / CID of stage IA-IC1 patients with or without chemotherapy were as follows: recurrence (13.0% (yes) / 9.6% (no)), death (9.3% (yes) / 4.2% (no)), respectively (P=0.947 (CIR) / P=0.224 (CID)). CCC patients staged greater than IC2/ IC3 show a marked risk of mortality, even after complete surgical resection.

    DOI： 10.18632/oncotarget.23921

    Scopus

    PubMed

  • Kosei Hasegawa, Masahiro Kagabu, Mika Mizuno, Katsutoshi Oda, Daisuke Aoki, Seiji Mabuchi, Shoji Kamiura, Satoshi Yamaguchi, Yoichi Aoki, Toshiaki Saito, Mayu Yunokawa, Kazuhiro Takehara, Aikou Okamoto, Kazunori Ochiai, Tadashi Kimura .  Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations .  INVESTIGATIONAL NEW DRUGS35 ( 6 ) 800 - 812   2017.12Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations

    　More details

    Publisher：SPRINGER  

    Objective Perifosine exhibits anti-tumor activity by inhibiting AKT phosphorylation. The purpose of this phase II basket trial was to evaluate the efficacy and safety of perifosine monotherapy for ovarian, endometrial, and cervical cancers. Methods Recurrent or persistent ovarian, endometrial, or cervical cancer patients were assigned to PIK3CA wild-type or mutant groups. Each patient received 600 mg oral perifosine on day 1 followed by a maintenance dose of 100 mg daily. The primary endpoint was disease control rate; secondary endpoints included response rate, progression-free survival, overall survival, and safety. Immunohistochemical staining and targeted sequencing were used to explore new biomarkers in such patients. Results Sixteen and 5 ovarian, 17 and 7 endometrial, and 18 and 8 cervical cancer patients with PIK3CA wild-type and mutant, respectively, were enrolled. Disease control rates (wild-type/mutant) were 12.5/40.0%, 47.1/14.3%, and 11.1/25.0% in ovarian, endometrial, and cervical cancer, respectively. The most common grade 3/4 toxicities were anemia (22.5%) and anorexia (11.3%). Immunohistochemical staining revealed that the disease control rate in patients with negative phosphatase and tensin homolog (PTEN) expression was 50.0%, and the odds ratio of positive to negative patients was 0.24 in all patients. Conclusions Perifosine monotherapy showed good tolerability but expected efficacy was not achieved. Modest efficacy was demonstrated in ovarian cancer patients with PIK3CA mutations and endometrial cancer patients with PIK3CA wild-type; no difference was observed between PIK3CA wild-type and mutant in cervical cancer. Absence of PTEN expression may be predictive of clinical efficacy with perifosine monotherapy.

    DOI： 10.1007/s10637-017-0504-6

    Web of Science

    PubMed

  • Albina N. Minlikeeva, Jo L. Freudenheim, Kevin H. Eng, Rikki A. Cannioto, Grace Friel, J. Brian Szender, Brahm Segal, Kunle Odunsi, Paul Mayor, Brenda Diergaarde, Emese Zsiros, Linda E. Kelemen, Martin Kobel, Helen Steed, Anna deFazio, Susan J. Jordan, Peter A. Fasching, Matthias W. Beckmann, Harvey A. Risch, Mary Anne Rossing, Jennifer A. Doherty, Jenny Chang-Claude, Marc T. Goodman, Thilo Doerk, Robert Edwards, Francesmary Modugno, Roberta B. Ness, Keitaro Matsuo, Mika Mizuno, Beth Y. Karlan, Ellen L. Goode, Susanne K. Kjaer, Estrid Hogdall, Joellen M. Schildkraut, Kathryn L. Terry, Daniel W. Cramer, Elisa V. Bandera, Lisa E. Paddock, Lambertus A. Kiemeney, Leon F. A. G. Massuger, Rebecca Sutphen, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Simon A. Gayther, Susan J. Ramus, Aleksandra Gentry-Maharaj, Celeste L. Pearce, Anna H. Wu, Jolanta Kupryjanczyk, Allan Jensen, Penelope M. Webb, Kirsten B. Moysich .  History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium .  CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION26 ( 9 ) 1470 - 1473   2017.9History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

    　More details

    Publisher：AMER ASSOC CANCER RESEARCH  

    Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.
    Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.
    Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).
    Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.
    Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. (C) 2017 AACR.

    DOI： 10.1158/1055-9965.EPI-17-0367

    Web of Science

    PubMed

  • Albina N. Minlikeeva, Jo L. Freudenheim, Rikki A. Cannioto, Kevin H. Eng, J. Brian Szender, Paul Mayor, John L. Etter, Daniel W. Cramer, Brenda Diergaarde, Jennifer A. Doherty, Thilo Doerk, Robert Edwards, Anna deFazio, Grace Friel, Marc T. Goodman, Peter Hillemanns, Estrid Hogdall, Allan Jensen, Susan J. Jordan, Beth Y. Karlan, Susanne K. Kjaer, Ruediger Klapdor, Keitaro Matsuo, Mika Mizuno, Christina M. Nagle, Kunle Odunsi, Lisa Paddock, Mary Anne Rossing, Joellen M. Schildkraut, Barbara Schmalfeldt, Brahm H. Segal, Kristen Starbuck, Kathryn L. Terry, Penelope M. Webb, Emese Zsiros, Roberta B. Ness, Francesmary Modugno, Elisa V. Bandera, Jenny Chang-Claude, Kirsten B. Moysich .  History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report .  BRITISH JOURNAL OF CANCER117 ( 7 ) 1063 - 1069   2017.9History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

    　More details

    Publisher：NATURE PUBLISHING GROUP  

    Background: Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.
    Methods: We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper-and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.
    Results: Overall, there was a nonsignificant association with history of hyperthyroidism (n = 160 cases) and mortality (HR = 1.22; 95% CI = 0.97-1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR = 1.94; 95% CI = 1.19-3.18). A more modest association was observed with history of hypothyroidism (n = 624 cases) and mortality (HR = 1.16; 95% CI = 1.03-1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.
    Conclusions: In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.

    DOI： 10.1038/bjc.2017.267

    Web of Science

    PubMed

  • Albina N. Minlikeeva, Jo L. Freudenheim, Rikki A. Cannioto, J. Brian Szender, Kevin H. Eng, Francesmary Modugno, Roberta B. Ness, Michael J. LaMonte, Grace Friel, Brahm H. Segal, Kunle Odunsi, Paul Mayor, Emese Zsiros, Barbara Schmalfeldt, Ruediger Klapdor, Thilo Doerk, Peter Hillemanns, Linda E. Kelemen, Martin Kobel, Helen Steed, Anna de Fazio, Susan J. Jordan, Christina M. Nagle, Harvey A. Risch, Mary Anne Rossing, Jennifer A. Doherty, Marc T. Goodman, Robert Edwards, Keitaro Matsuo, Mika Mizuno, Beth Y. Karlan, Susanne K. Kjaer, Estrid Hogdall, Allan Jensen, Joellen M. Schildkraut, Kathryn L. Terry, Daniel W. Cramer, Elisa V. Bandera, Lisa E. Paddock, Lambertus A. Kiemeney, Leon F. Massuger, Jolanta Kupryjanczyk, Andrew Berchuck, Jenny Chang-Claude, Brenda Diergaarde, Penelope M. Webb, Kirsten B. Moysich .  History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium .  CANCER CAUSES & CONTROL28 ( 5 ) 469 - 486   2017.5History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium

    　More details

    Publisher：SPRINGER  

    Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.
    Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.
    History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.
    Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.

    DOI： 10.1007/s10552-017-0867-1

    Web of Science

    PubMed

  • Fumi Utsumi, Hiroaki Kajiyama, Kaoru Niimi, Ryuichiro Sekiya, Jun Sakata, Shiro Suzuki, Kiyosumi Shibata, Mika Mizuno, Fumitaka Kikkawa .  Clinical significance and predicting indicators of post-cancer-treatment survival in terminally ill patients with ovarian cancer .  JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH43 ( 2 ) 365 - 370   2017.2Clinical significance and predicting indicators of post-cancer-treatment survival in terminally ill patients with ovarian cancer

    　More details

    Publisher：WILEY  

    AimWomen with ovarian cancer (OC) often experience relapse and receive further repetitive chemotherapy. The objective of this study was to overview the remaining survival time after the final chemotherapy and to examine influential clinicopathologic indicators in those patients.
    MethodsThe medical charts of deceased OC patients who had died of the disease between 2003 and 2012 were retrospectively reviewed. We investigated post-cancer-treatment survival (PCS) defined as the interval between the date of the final chemotherapy and death.
    ResultsIn all, 77 patients were enrolled. Three patients (3.9%) had received chemotherapy in the last 2 weeks. Eight (10.4%), 28 (36.4%), and 44 (57.2%) patients had received chemotherapy in the last 30, 60, and 90 days, respectively. There were no differences in either survival after recurrence or overall survival between the shorter (&lt;75 days) and longer (75 days) PCS groups. On the other hand, patients in the shorter PCS group had significantly fewer chances of referral to a hospice or home-care than those in the latter group (P=0.035). In multivariable analysis, a poorer performance status, an elevated white blood cell count, and a higher C-reactive protein value were significantly correlated with a shorter PCS (P=0.004, 0.006 and 0.027, respectively).
    ConclusionHalf of the patients received chemotherapy within 75 days of death and we did not identify any survival benefit in patients who received chemotherapy near the end of life. We should provide information to patients about their prognosis and discuss the timing of withdrawal from chemotherapy from the early stage of their recurrence.

    DOI： 10.1111/jog.13219

    Web of Science

    PubMed

  • Utsumi Fumi, Kajiyama Hiroaki, Niimi Kaoru, Sekiya Ryuichiro, Sakata Jun, Suzuki Shiro, Shibata Kiyosumi, Mizuno Mika, Kikkawa Fumitaka .  末期卵巣癌患者における癌治療後生存期間の臨床的意義と予測指標(Clinical significance and predicting indicators of post-cancer-treatment survival in terminally ill patients with ovarian cancer) .  The Journal of Obstetrics and Gynaecology Research43 ( 2 ) 365 - 370   2017.2末期卵巣癌患者における癌治療後生存期間の臨床的意義と予測指標(Clinical significance and predicting indicators of post-cancer-treatment survival in terminally ill patients with ovarian cancer)

    　More details

    Publisher：John Wiley & Sons Australia, Ltd  

    卵巣癌(OC)患者に対して最後に実施した化学療法後の生存期間に関する臨床病理学的指標について後向きに検討した。2003-2012年に病死したOC患者77名(入院時年齢中央値58.3歳)を対象とした。最後の化学療法実施日から死亡日までの期間である癌治療後生存期間(PCS)を検証した。3例では最後の2週間に化学療法が施行された。8例、28例、44例では、それぞれ最後の30日、60日、90日に化学療法が施行された。PCSが短い群(75日未満)と長い群(75日以上)の間で、再発後生存期間または全生存期間に差は認められなかった。PCSが短い群では、ホスピスや在宅ケアへの紹介率が、PCSが長い群よりも有意に低かった。多変量解析の結果、全身状態の不良、白血球数の増加、高CRP値が、より短いPCSと相関していた。

  • Toru Sugiyama, Mika Mizuno, Yoichi Aoki, Manabu Sakurai, Tadaaki Nishikawa, Eisuke Ueda, Kosei Tajima, Nobuhiro Takeshima .  A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer .  JAPANESE JOURNAL OF CLINICAL ONCOLOGY47 ( 1 ) 39 - 46   2017.1A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer

    　More details

    Publisher：OXFORD UNIV PRESS  

    Background: Adding bevacizumab to chemotherapy for recurrent, persistent or metastatic cervical cancer significantly improved overall survival (primary endpoint), progression-free survival and overall response rate in the randomized Phase III GOG-0240 trial. However, data for bevacizumab-containing therapy are scarce in Japanese patients with advanced cervical cancer.
    Methods: The primary objective of the single-arm multicenter Phase II JO29569 study was to evaluate the tolerability of paclitaxel (135 mg/m(2) over 24 h or 175 mg/m(2) over 3 h), cisplatin (50 mg/m(2)) and bevacizumab (15 mg/kg), administered every 3 weeks until disease progression or unacceptable toxicity in Japanese patients with stage IVB, persistent or recurrent cervical cancer.
    Results: The seven treated patients received a median of nine (range 7-12) bevacizumab cycles and six (range 4-12) chemotherapy cycles. None of the predefined adverse events occurred during the tolerability evaluation period. The most common all-grade adverse events were alopecia, hypertension, decreased appetite, nausea and peripheral sensory neuropathy. There were no cases of fistula. The most common grade &gt;= 3 adverse events were hypertension, neutrophil count decreased and neutropenia. Only one patient experienced febrile neutropenia. The overall response rate was 86% (95% confidence interval, 42-100%), including a complete response in one patient. At data cutoff, disease had progressed in one patient; bevacizumab therapy was ongoing in the remaining six.
    Conclusions: According to the specified primary objective, a regimen of cisplatin, paclitaxel and bevacizumab was tolerable in Japanese patients and demonstrated encouraging activity in this small single-arm study. Further study is warranted to confirm the safety and effectiveness of bevacizumab in Japanese patients with cervical cancer.

    DOI： 10.1093/jjco/hyw143

    Web of Science

    PubMed

  • Sugiyama Toru, Mizuno Mika, Aoki Yoichi, Sakurai Manabu, Nishikawa Tadaaki, Ueda Eisuke, Tajima Kosei, Takeshima Nobuhiro .  日本人進行性子宮頸癌患者におけるベバシズマブ、シスプラチン、パクリタキセル投与後のベバシズマブ単剤投与を評価する単一群試験(A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer) .  Japanese Journal of Clinical Oncology47 ( 1 ) 39 - 46   2017.1日本人進行性子宮頸癌患者におけるベバシズマブ、シスプラチン、パクリタキセル投与後のベバシズマブ単剤投与を評価する単一群試験(A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer)

    　More details

    Publisher：Oxford University Press  

    ステージIVBの持続性/再発性子宮頸癌患者7例(34〜69歳)を対象に、ベバシズマブ併用療法の安全性と有効性を評価する第II相試験を実施した。7例に対し、パクリタキセル、シスプラチン、ベバシズマブを疾患進行または認容不能な毒性が出現するまで3週ごとに投与した。忍容性評価期間中に忍容性評価基準に該当する有害事象は起こらなかった。7例で、グレード4を含むグレード3以上の有害事象を3件(43%)経験したが、致死的な有害事象はなかった。最も頻度の高い全グレードの有害事象は脱毛、高血圧、食欲減少、嘔気、末梢感覚神経障害であった。最も頻度の高いグレード3以上の有害事象は高血圧、好中球数減少、好中球減少症であった。1例のみが発熱性好中球減少症を経験した。全奏効率は86%(95%信頼区間42〜100%)で、完全奏効は1例であった。1例で疾患が進行し、残り6例はベバシズマブ投与中であった。日本人子宮頸癌患者においてシスプラチン、パクリタキセル、ベバシズマブの併用投与は忍容性が良好で、有効性も有望であることが示唆された。

▼display all

MISC

  • 異型腺細胞Atypical glandular cells(AGC)の取り扱い　現場のアンケート調査結果も加えて

    水野 美香

    鹿児島産科婦人科学会雑誌   31   1 - 7   2023.3

    　More details

    Language：Japanese   Publisher：鹿児島産科婦人科学会  

  • 失敗から学ぶ　手術におけるわれわれの取組みやコツ　ロボット　骨盤臓器脱に対するallograftを用いたロボット支援仙骨腟固定術の試み

    牛若 昂志, 徳留 明夫, 泉 明延, 小林 裕介, 福田 美香, 水野 美香, 簗詰 伸太郎, 戸上 真一, 神尾 真樹, 小林 裕明

    産婦人科手術   ( 33 )   99 - 104   2022.6

    　More details

    Language：Japanese   Publisher：(株)メジカルビュー社  

  • 子宮頸部上皮内腫瘍/頸部扁平上皮内病変(CIN/SIL)の管理と新規治療の取り組み　5-アミノレブリン酸を用いた光線力学的療法の臨床試験結果より

    水野 美香

    鹿児島産科婦人科学会雑誌   29   1 - 8   2021.3

    　More details

    Language：Japanese   Publisher：鹿児島産科婦人科学会  

    子宮頸癌の前駆病変である子宮頸部上皮内腫瘍(CIN)の早期発見および治療は、子宮温存および死亡率低下に重要である。子宮頸部上皮内病変の分類について、従来のCIN分類から扁平上皮内病変(SIL)分類を含む2020年WHO分類まで解説した。また、筆者らが行ってきたLED光を用いた光線力学的療法と5-アミノレブリン酸の局所投与を併用したCIN治療の臨床試験結果を紹介した。

  • 【産婦人科領域におけるレーザー診療の最前線】子宮頸部上皮内腫瘍(CIN)に対する5-aminolevulinic acidを用いた光線力学的療法

    水野 美香

    産婦人科の実際   69 ( 9 )   951 - 956   2020.9

    　More details

    Publisher：金原出版(株)  

    ＜文献概要＞光線力学的療法(PDT)は,親和性の高い光感受性物質が集積した腫瘍に,励起光を照射し,その光化学反応によりアポトーシスを誘導,殺細胞効果を利用した低侵襲性がん治療の1つである。増感剤を投与してレーザー光を照射するPDTが,子宮頸部上皮内腫瘍(CIN)3の治療として保険収載されている。本稿では,CINに対して,増感作用をもたないアミノ酸の一種5-aminolevulinic acidとLED光源を用い,外来ベースで行った新しいPDTについて臨床試験の結果を踏まえて解説する。

  • 【どうする再発婦人科がん】肺再発

    水野 美香

    産科と婦人科   86 ( 10 )   1221 - 1225   2019.10

    　More details

    Publisher：(株)診断と治療社  

    婦人科がんの肺実質単独の転移は少なく、同時性・異時性にリンパ節転移、腹膜転移巣など複数伴うことが多い。高頻度マイクロサテライト不安定性固形がんに対して免疫チェックポイント阻害薬の適応が拡大され、今後の予後改善が期待されるが、実際に適用される症例は多くない。他臓器腫瘍に比べて、婦人科領域では薬物療法の選択肢が少なく、難治性癌のマネジメントは日常診療の課題である。本稿では、肺転移に対する外科的治療や薬物療法の治療戦略を検討した。(著者抄録)

  • 日本婦人科腫瘍学会の子宮頸癌治療ガイドライン2017年版(Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer)

    Ebina Yasuhiko, Mikami Mikio, Nagase Satoru, Tabata Tsutomu, Kaneuchi Masanori, Tashiro Hironori, Mandai Masaki, Enomoto Takayuki, Kobayashi Yoichi, Katabuchi Hidetaka, Yaegashi Nobuo, Udagawa Yasuhiro, Aoki Daisuke, Mikami Mikio, Nagase Satoru, Tabata Tsutomu, Udagawa Yasuhiro, Yaegashi Nobuo, Baba Tsukasa, Enomoto Takayuki, Hayashi Kazuhiko, Hirashima Yasuyuki, Iwata Takashi, Kato Shingo, Katsumata Noriyuki, Kojima Atsumi, Kurokawa Tetsuji, Mandai Masaki, Mikami Yoshiki, Muramatsu Toshinari, Nagai Yutaka, Nakai Hidekatsu, Nakayama Kentaro, Niikura Hitoshi, Oda Katsutoshi, Ohtake Hideyuki, Sekine Masayuki, Shimada Muneaki, Tabata Tsutomu, Takaishi Kiyomi, Takamatsu Kiyoshi, Takehara Kazuhiro, Toita Takafumi, Yamaguchi Satoshi, Yasuda Masanori, Yoshino Kiyoshi, Aoki Yoichi, Fujii Takuma, Fujiwara Keiichi, Hachisuga Toru, Hamatani Toshio, Hrano Kenichi, Ino Kazuhiko, Itakura Atsuko, Ito Kiyoshi, Iwanari Osamu, Kamoi Seiryu, Kasamatsu Takahiro, Kawamura Naoki, Kobayashi Hiroaki, Kobayashi Hiroshi, Kodaira Takeshi, Kubushiro Kaneyuki, Miyagi Etsuko, Mizuno Mika, Morishige Kenichiro, Nagasaka Tetsuro, Nakamura Toshiaki, Ohmichi Masahide, Okamoto Aikou, Onda Takashi, Saito Tsuyoshi, Saito Toshiaki, Sakuragi Noriaki, Sato Toyomi, Shiraishi Tadashi, Sugiyama Toru, Suzuki Nao, Suzuki Mitsuaki, Takano Masashi, Takeshima Nobuhiro, Uno Takashi, Ushijima Kimio, Watanabe Yoh, Yokota Hiroko, Yoshikawa Hiroyuki, Japan Society of Gynecologic Oncology

    International Journal of Clinical Oncology   24 ( 1 )   1 - 19   2019.1

    　More details

    Publisher：シュプリンガー・ジャパン(株)  

  • 腹腔鏡下子宮体癌術後に発生したポートサイトヘルニアの1例

    坪内 寛文, 森 正彦, 坂田 純, 水野 美香

    日本産科婦人科内視鏡学会雑誌   34 ( Suppl.I )   192 - 192   2018.8

    　More details

    Publisher：(一社)日本産科婦人科内視鏡学会  

  • 進行性平滑筋肉腫の治療成績

    小澤 英史, 吉田 雅博, 林 卓馬, 安藤 正志, 水野 美香, 室 圭, 清水 泰博, 谷田部 恭, 小森 康司, 本多 和典, 筑紫 聡

    日本整形外科学会雑誌   92 ( 6 )   S1546 - S1546   2018.6

    　More details

    Publisher：(公社)日本整形外科学会  

  • 肺癌子宮転移の1例

    竹下 奨, 坪内 寛文, 坂田 純, 森 正彦, 水野 美香

    日本臨床細胞学会雑誌   57 ( Suppl.1 )   290 - 290   2018.4

    　More details

    Publisher：(公社)日本臨床細胞学会  

  • 尿路生殖器への広範なpagetoid spreadを認めた子宮頸部腺癌の一例

    宇野 あす香, 清水 裕介, 森 正彦, 近藤 紳司, 水野 美香

    東海産科婦人科学会雑誌   54   314 - 314   2018.3

    　More details

    Publisher：東海産科婦人科学会  

  • 異なる転機をたどった外陰部類上皮肉腫の2例

    森 正彦, 宇野 あす香, 清水 裕介, 近藤 紳司, 水野 美香, 谷田部 恭

    東海産科婦人科学会雑誌   54   317 - 317   2018.3

    　More details

    Publisher：東海産科婦人科学会  

  • 進行・再発子宮頸癌に対してBevacizumabを使用した15例の検討

    坪内 寛文, 水野 美香, 近藤 紳司, 森 正彦, 服部 諭美

    日本産科婦人科学会雑誌   70 ( 2 )   757 - 757   2018.2

    　More details

    Publisher：(公社)日本産科婦人科学会  

  • ロボット支援腹腔鏡下子宮全摘術の導入

    水野 美香, 森 正彦, 井坂 惠一

    日本内視鏡外科学会雑誌   22 ( 7 )   EP122 - 07   2017.12

    　More details

    Publisher：(一社)日本内視鏡外科学会  

  • 婦人科悪性腫瘍に対する腹腔鏡下手術の転帰 case reportsより

    水野 美香, 服部 諭美, 坪内 寛文, 森 正彦, 近藤 紳司

    愛知産科婦人科学会学術講演会プログラム   106回   16 - 16   2017.10

    　More details

    Publisher：愛知産科婦人科学会  

  • 産婦人科領域におけるレーザー治療の現状と展望 子宮頸部上皮内腫瘍に対する5-aminolevnic acidを用いたphotodynamic therapyの検討 臨床試験結果より

    水野 美香

    日本レーザー医学会誌   38 ( 3 )   267 - 267   2017.10

    　More details

    Publisher：(NPO)日本レーザー医学会  

  • 日本の婦人科がん高齢患者の相対生存率

    井上 修作, 伊藤 秀美, 細野 覚代, 水野 美香, 加藤 聖子, 松尾 恵太郎

    日本癌学会総会記事   76回   P - 2381   2017.9

    　More details

    Publisher：日本癌学会  

  • 初期卵巣癌に対する妊孕性温存手術 拡大vs温存 傾向スコア用いた長期生存解析の結果から

    梶山 広明, 河井 通泰, 水野 公雄, 山室 理, 小口 秀紀, 水野 美香, 吉川 史隆

    日本婦人科腫瘍学会雑誌   35 ( 3 )   552 - 552   2017.6

    　More details

    Publisher：(公社)日本婦人科腫瘍学会  

  • 乳癌既往を有する子宮体がん73症例の検討

    森 正彦, 宇野 あす香, 清水 裕介, 近藤 紳司, 水野 美香

    日本産科婦人科学会雑誌   69 ( 2 )   801 - 801   2017.2

    　More details

    Publisher：(公社)日本産科婦人科学会  

  • 後期高齢者に対する子宮頸がん治療の現状

    宇野 あす香, 清水 裕介, 森 正彦, 近藤 紳司, 水野 美香

    日本産科婦人科学会雑誌   69 ( 2 )   794 - 794   2017.2

    　More details

    Publisher：(公社)日本産科婦人科学会  

  • 卵巣明細胞癌における5-aminolevulinic acidを用いた光線力学療法の検討

    勅使河原, 利哉, 水野 美香, 坂田 純, 内海 史, 関谷 龍一郎, 鈴木 史朗, 梶山 広明, 柴田 清住, 吉川 史隆

    日本産科婦人科学会雑誌   69 ( 2 )   689 - 689   2017.2

    　More details

    Publisher：(公社)日本産科婦人科学会  

▼display all

Presentations

  • 牛若 昂志, 徳留 明夫, 泉 明延, 小林 裕介, 福田 美香, 水野 美香, 簗詰 伸太郎, 戸上 真一, 神尾 真樹, 小林 裕明   骨盤臓器脱に対するallograftを用いたロボット支援仙骨腟固定術の試み  

    産婦人科手術  2022.6  (株)メジカルビュー社

    　More details

    Language：Japanese  

  • 牛若 昂志, 徳留 明夫, 泉 明延, 小林 裕介, 福田 美香, 水野 美香, 簗詰 伸太郎, 戸上 真一, 神尾 真樹, 小林 裕明   骨盤臓器脱に対するAllograftを用いたロボット支援仙骨腟固定術の試み  

    日本産科婦人科内視鏡学会雑誌  2021.9  (一社)日本産科婦人科内視鏡学会

    　More details

    Language：Japanese  

  • 水野 美香, 永田 真子, 小林 裕介, 牛若 昂志, 福田 美香, 簗詰 伸太郎, 戸上 真一, 神尾 真樹, 小林 裕明   進行卵巣癌に対するBevacizumab併用術前化学療法の効果判定に対する検討  

    日本婦人科腫瘍学会学術講演会プログラム・抄録集  2021.7  (公社)日本婦人科腫瘍学会

    　More details

    Language：Japanese  

  • 簗詰 伸太郎, 牛若 昂志, 黒田 高史, 福田 美香, 水野 美香, 戸上 真一, 神尾 真樹, 小林 裕明   進行卵巣癌における初回増悪後の生存期間(SPP)に関する検討  

    日本婦人科腫瘍学会学術講演会プログラム・抄録集  2021.7  (公社)日本婦人科腫瘍学会

    　More details

    Language：Japanese  

  • 坪内 寛文, 坂田 純, 森 正彦, 水野 美香   頸部細胞診AGC判定により分葉状頸管性過形成の診断に苦慮した一例  

    日本臨床細胞学会雑誌  2018.10  (公社)日本臨床細胞学会

  • 小澤 英史, 吉田 雅博, 林 卓馬, 安藤 正志, 水野 美香, 室 圭, 清水 泰博, 谷田部 恭, 小森 康司, 本多 和典, 筑紫 聡   進行性平滑筋肉腫の治療成績  

    日本整形外科学会雑誌  2018.6  (公社)日本整形外科学会

  • 坪内 寛文, 坂田 純, 森 正彦, 水野 美香   進行・再発子宮頸部小細胞癌に対してBevacizumabを使用した3例  

    愛知産科婦人科学会学術講演会プログラム  2018.6  愛知産科婦人科学会

  • 坪内 寛文, 水野 美香, 近藤 紳司, 森 正彦, 服部 諭美   進行・再発子宮頸癌に対してBevacizumabを使用した15例の検討  

    日本産科婦人科学会雑誌  2018.2  (公社)日本産科婦人科学会

  • 野村 弘行, 青木 大輔, 水野 美香, 新井 正秀, 西尾 真, 田部 宏, 徳永 英樹, 中西 透, 渡部 洋, 八重樫 伸生, 横山 良仁, 竹原 和宏   術後補助化学療法施行後の子宮体癌再発パターンおよびリスク因子に関する検討(JGOG2043A-1研究)  

    日本婦人科腫瘍学会雑誌  2019.6  (公社)日本婦人科腫瘍学会

  • Shimizu Yusuke, Mizuno Mika, Kondo Shinji, Mori Masahiko, Uno Asuka   臨床的かつ外科的病期IVの子宮内膜癌を有する全患者集団における長期予後因子の評価(Evaluating the long term prognostic factor in the overall population of patients with clinical and surgical stage IV endometrial carcinoma)  

    The Journal of Obstetrics and Gynaecology Research  2017.12  John Wiley & Sons Australia, Ltd

  • Shimizu Yusuke, Mizuno Mika, Kondo Shinji, Mori Masahiko, Uno Asuka   臨床的および外科的ステージIV子宮内膜癌患者の全体集団における長期予後因子の評価(Evaluating the long term prognostic factor in the overall population of patients with clinical and surgical stage IV endometrial carcinoma)  

    日本産科婦人科学会雑誌  2017.2  (公社)日本産科婦人科学会

  • 坪内 寛文, 森 正彦, 坂田 純, 水野 美香   腹腔鏡下子宮体癌術後に発生したポートサイトヘルニアの1例  

    日本産科婦人科内視鏡学会雑誌  2018.8  (一社)日本産科婦人科内視鏡学会

  • 竹下 奨, 坪内 寛文, 坂田 純, 森 正彦, 水野 美香   肺癌子宮転移の1例  

    日本臨床細胞学会雑誌  2018.4  (公社)日本臨床細胞学会

  • 森 正彦, 宇野 あす香, 清水 裕介, 近藤 紳司, 水野 美香, 谷田部 恭   異なる転機をたどった外陰部類上皮肉腫の2例  

    東海産科婦人科学会雑誌  2018.3  東海産科婦人科学会

  • 水野 美香   産婦人科領域における光線力学診断、光線力学療法の最前線　子宮頸部上皮内病変に対する新規治療戦略　5-aminolevulinic acidとLEDを用いた光線力学的治療  

    日本レーザー医学会誌  2020.9  (NPO)日本レーザー医学会

  • 水野 美香   産婦人科領域におけるレーザー治療の現状と展望　子宮頸部上皮内腫瘍に対する5-aminolevnic acidを用いたphotodynamic therapyの検討　臨床試験結果より  

    日本レーザー医学会誌  2017.10  (NPO)日本レーザー医学会

  • 井上 修作, 伊藤 秀美, 細野 覚代, 水野 美香, 加藤 聖子, 松尾 恵太郎   日本の婦人科がん高齢患者の相対生存率  

    日本癌学会総会記事  2017.9  (一社)日本癌学会

  • 宇野 あす香, 清水 裕介, 森 正彦, 近藤 紳司, 水野 美香   後期高齢者に対する子宮頸がん治療の現状  

    日本産科婦人科学会雑誌  2017.2  (公社)日本産科婦人科学会

  • 水野 美香, 森 正彦, 服部 諭美, 近藤 紳司   当院における子宮頸癌に対するロボット支援腹腔鏡下子宮全摘術の導入  

    日本産科婦人科内視鏡学会雑誌  2017.8  (一社)日本産科婦人科内視鏡学会

  • 宇野 あす香, 清水 裕介, 森 正彦, 近藤 紳司, 水野 美香   尿路生殖器への広範なpagetoid spreadを認めた子宮頸部腺癌の一例  

    東海産科婦人科学会雑誌  2018.3  東海産科婦人科学会

  • 長井 裕, 三上 幹男, 武隈 宗孝, 喜多川 亮, 長尾 昌二, 戸澤 晃子, 西尾 真, 小林 栄仁, 生水 真紀夫, 宮城 悦子, 横田 治重, 笠松 由佳, 青木 陽一, 岩瀬 春子, 山口 聡, 苛原 稔, 横山 正俊, 八重樫 伸生, 増山 寿, 竹原 和宏, 中村 俊昭, 青木 大輔, 早瀬 良二, 中村 和人, 田畑 務, 上浦 祥司, 岩佐 尚美, 平澤 猛, 杉野 法広, 塩沢 丹里, 小林 浩, 松元 隆, 森重 健一郎, 北 正人, 板持 広明, 菊池 朗, 杉浦 真弓, 藤原 葉一郎, 徳山 治, 大石 徹郎, 小林 裕明, 渡利 英道, 水野 美香, 吉田 好雄, 村上 文洋, 高橋 慶行, 横井 猛, 楢原 久司, 小寺 宏平, 横山 良仁, 沖 明典, 中西 慶喜, 水之江 知哉, 杉山 徹   子宮頸部腺癌に対する同時化学放射線療法に関する多施設共同調査研究  

    日本産科婦人科学会雑誌  2019.2  (公社)日本産科婦人科学会

  • 川村 麻里子, 小出 雄太郎, 村井 太郎, 石原 俊一, 高瀬 裕樹, 村尾 豪之, 岡崎 大, 山口 尊弘, 内山 薫, 伊藤 善之, 古平 毅, 芝本 雄太, 水野 美香, 吉川 史隆, 長縄 慎二   子宮頸部小細胞癌の治療法とその予後に関する実態調査　多施設による遡及的調査  

    日本婦人科腫瘍学会雑誌  2021.1  (公社)日本婦人科腫瘍学会

  • Mizuno Mika   子宮頸部上皮内腫瘍(CIN)の管理　子宮頸部上皮内腫瘍の新たな低侵襲治療　5-aminolevulinic acidを用いた光線力学的治療の臨床試験(Management of Cervical Intraepithelial Neoplasia(CIN)　New minimally invasive treatment of cervical intraepithelial Neoplasia: A clinical trial of Photodynamic therapy using 5-Aminolevulinic acid)  

    日本婦人科腫瘍学会雑誌  2018.6  (公社)日本婦人科腫瘍学会

  • 戸上 真一, 黒田 高史, 牛若 昂, 福田 美香, 水野 美香, 簗詰 伸太郎, 神尾 真樹, 小林 裕明   子宮体癌に対する腹腔鏡手術(術式選択やセンチネルリンパ節生検含む)　子宮体がんに対する鏡視下センチネルノードナビゲーション手術(SNNS)  

    日本産科婦人科内視鏡学会雑誌  2020.11  (一社)日本産科婦人科内視鏡学会

  • 水野 美香   婦人科領域におけるレーザー医療の進歩と課題　子宮頸部上皮内腫瘍に対する5-aminolevnic acidを用いたphotodynamic therapの検討  

    日本レーザー医学会誌  2019.9  (NPO)日本レーザー医学会

  • 坪内 寛文, 坂田 純, 森 正彦, 水野 美香   婦人科悪性腫瘍手術後におけるアセトアミノフェン静注剤定期投与の鎮痛効果の検討  

    日本産科婦人科学会雑誌  2019.2  (公社)日本産科婦人科学会

  • 水野 美香, 服部 諭美, 坪内 寛文, 森 正彦, 近藤 紳司   婦人科悪性腫瘍に対する腹腔鏡下手術の転帰　case reportsより  

    愛知産科婦人科学会学術講演会プログラム  2017.10  愛知産科婦人科学会

  • 勅使河原 利哉, 水野 美香, 坂田 純, 内海 史, 関谷 龍一郎, 鈴木 史朗, 梶山 広明, 柴田 清住, 吉川 史隆   卵巣明細胞癌における5-aminolevulinic acidを用いた光線力学療法の検討  

    日本産科婦人科学会雑誌  2017.2  (公社)日本産科婦人科学会

  • Ito Kimihiko, Mizuno Mika, Nakai Hidekatsu, Kato Hidenori, Kamiura Shoji, Ushijima Kimio, Nagao Shoji, Takano Hirokuni, Okadome Masao, Takekuma Munetaka, Tokunaga Hideki, Nagase Satoru, Aoki Daisuke, Coleman Robert L., Dinh Minh H., Sullivan Danielle, Hashiba Hideyuki, Xiong Hao, Katsumata Noriyuki, Okamoto Aikou   卵巣/卵管/腹膜の高異型度漿液性上皮癌(HGSC)の日本人女性患者における第一選択化学療法と併用したベリパリブ療法および単剤療法としてのベリパリブ療法(Veliparib Combined with Front-line Chemotherapy and as Monotherapy in Japanese Women with High-grade Serous Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Carcinoma(HGSC))  

    日本婦人科腫瘍学会雑誌  2021.1  (公社)日本婦人科腫瘍学会

  • Mizuno Mika, Mori Masahiko, Hattori Satomi, Kondo Shinji   初期子宮頸癌に対するロボット支援腹腔鏡下子宮摘出術の有用性と安全性の研究　経過報告書(The study of utility and safety of robot-assisted laparoscopic hysterectomy for early-stage cervical cancer: Progress reports)  

    日本産科婦人科内視鏡学会雑誌  2017.8  (一社)日本産科婦人科内視鏡学会

  • 梶山 広明, 河井 通泰, 水野 公雄, 山室 理, 小口 秀紀, 水野 美香, 吉川 史隆   初期卵巣癌に対する妊孕性温存手術　拡大vs温存　傾向スコア用いた長期生存解析の結果から  

    日本婦人科腫瘍学会雑誌  2017.6  (公社)日本婦人科腫瘍学会

  • 森 正彦, 宇野 あす香, 清水 裕介, 近藤 紳司, 水野 美香   乳癌既往を有する子宮体がん73症例の検討  

    日本産科婦人科学会雑誌  2017.2  (公社)日本産科婦人科学会

  • 水野 美香, 森 正彦, 井坂 惠一   ロボット支援腹腔鏡下子宮全摘術の導入  

    日本内視鏡外科学会雑誌  2017.12  (一社)日本内視鏡外科学会

  • 神尾 真樹, 牛若 昂志, 福田 美香, 水野 美香, 簗詰 伸太郎, 戸上 真一, 小林 裕明   ロボット手術の安全な普及に向けて　我々の行っているロボット手術と安全に関する取り組み  

    日本産科婦人科内視鏡学会雑誌  2020.11  (一社)日本産科婦人科内視鏡学会

  • Kamio Masaki, Ushiwaka Takashi, Yorouki Honami, Karakida Noriko, Uchida Natsuko, Sakihama Mika, Mizuno Mika, Yanazume Shintaro, Togami Shinichi, Kobayashi Hiroaki   Evaluation of HPV test usefulness using urine sample as a screening for cervical cancer(和訳中)  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：English  

  • Kamio Masaki, Ushiwaka Takashi, Yorouki Honami, Karakida Noriko, Uchida Natsuko, Sakihama Mika, Mizuno Mika, Yanazume Shintaro, Togami Shinichi, Kobayashi Hiroaki   Evaluation of HPV test usefulness using urine sample as a screening for cervical cancer(和訳中)  

    The Journal of Obstetrics and Gynaecology Research  2021.8  John Wiley & Sons Australia, Ltd

    　More details

    Language：English  

  • 竹歳 杏子, 簗詰 伸太郎, 黒田 高史, 牛若 昂志, 福田 美香, 水野 美香, 戸上 真一, 神尾 真樹, 小林 裕明   McIndoe変法を施行した先天性腟欠損症(Mayer-Rokitansky-Kuester-Hauser症候群)の4症例  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 黒田 高史, 簗詰 伸太郎, 牛若 昴志, 福田 美香, 水野 美香, 戸上 真一, 神尾 真樹, 小林 裕明   ロボット支援子宮体癌手術において術中に開腹術に移行した症例の検討  

    産婦人科手術  2021.6  (株)メジカルビュー社

    　More details

    Language：Japanese  

  • 戸上 真一, 牛若 昂志, 福田 美香, 水野 美香, 簗詰 伸太郎, 神尾 真樹, 小林 裕明   卵巣癌初回治療におけるbevacizumab併用のPFSとPFIに関する効果の検討  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 牛若 昂志, 黒田 高史, 福田 美香, 水野 美香, 簗詰 伸太郎, 戸上 真一, 神尾 真樹, 小林 裕明   広汎子宮全摘出術後膀胱腟瘻に対するModified Martius Flapを用いた経腟的修復術の1例  

    産婦人科手術  2021.6  (株)メジカルビュー社

    　More details

    Language：Japanese  

  • 簗詰 伸太郎, 黒田 高史, 牛若 昴志, 福田 美香, 水野 美香, 戸上 真一, 神尾 真樹, 小林 裕明   肥満症例におけるデュアルドッキング手術の検討と課題  

    産婦人科手術  2021.6  (株)メジカルビュー社

    　More details

    Language：Japanese  

  • 小林 裕介, 簗詰 伸太郎, 太崎 友紀子, 黒田 高史, 牛若 昂志, 福田 美香, 水野 美香, 戸上 真一, 神尾 真樹, 小林 裕明   若年で子宮体癌を発症した歌舞伎症候群の1例  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 簗詰 伸太郎, 牛若 昂志, 黒田 高史, 福田 美香, 水野 美香, 戸上 真一, 神尾 真樹, 小林 裕明   進行卵巣癌における初回治療後の増悪後生存期間(Postprogression Survival)に関する検討  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 牛若 昂志, 黒田 高史, 福田 美香, 水野 美香, 簗詰 伸太郎, 戸上 真一, 神尾 真樹, 小林 裕明   ダヴィンチXiシステムを用いた子宮体がんデュアルドッキング手術  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 簗詰 伸太郎, 牛若 昴志, 福田 美香, 水野 美香, 戸上 真一, 神尾 真樹, 小林 裕明   進行卵巣癌での初回治療後の増悪後生存期間(Postprogression Survival)に関する検討  

    日本癌治療学会学術集会抄録集  2021.10  (一社)日本癌治療学会

    　More details

    Language：English  

  • 水野 美香, 小林 裕介, 牛若 昂志, 簗詰 伸太郎, 戸上 真一, 切田 ゆかり, 窪田 恵美, 岩切 かおり, 東 美智代, 小林 裕明   臨床現場におけるAGCのマネージメントの実際　AGC管理の現状と課題　細胞診従事者を対象に行った実態調査のアンケート結果より  

    日本臨床細胞学会雑誌  2022.5  (公社)日本臨床細胞学会

    　More details

    Language：Japanese  

  • 水野 美香   産婦人科領域におけるレーザー治療の最前線　婦人科腫瘍と5-aminolevnic acidを用いたphotodynamic therapyの検討  

    日本レーザー医学会誌  2021.9  (NPO)日本レーザー医学会

    　More details

    Language：Japanese  

  • 永田 真子, 水野 美香, 福田 美香, 小林 裕介, 黒田 高史, 牛若 昂志, 簗詰 伸太郎, 戸上 真一, 神尾 真樹, 赤羽 俊章, 北薗 育美, 谷本 昭英, 小林 裕明   水腎症を合併し悪性卵巣腫瘍との鑑別を要したXanthogranulomatous inflammationの1例  

    日本婦人科腫瘍学会学術講演会プログラム・抄録集  2021.7  (公社)日本婦人科腫瘍学会

    　More details

    Language：Japanese  

  • Kamio Masaki, Ushiwaka Takashi, Yorouki Honami, Karakida Noriko, Uchida Natsuko, Sakihama Mika, Mizuno Mika, Yanazume Shintaro, Togami Shinichi, Kobayashi Hiroaki   子宮頸癌のスクリーニングにおける尿サンプルを用いたHPV検査の有用性評価(Evaluation of HPV test usefulness using urine sample as a screening for cervical cancer)  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：English  

  • Kamio Masaki, Ushiwaka Takashi, Yorouki Honami, Karakida Noriko, Uchida Natsuko, Sakihama Mika, Mizuno Mika, Yanazume Shintaro, Togami Shinichi, Kobayashi Hiroaki   子宮頸癌のスクリーニングにおける尿サンプルを用いたHPV検査の有用性評価(Evaluation of HPV test usefulness using urine sample as a screening for cervical cancer)  

    The Journal of Obstetrics and Gynaecology Research  2021.8  John Wiley & Sons Australia, Ltd

    　More details

    Language：English  

  • 戸上 真一, 永田 真子, 牛若 昂志, 福田 美香, 水野 美香, 簗詰 伸太郎, 神尾 真樹, 小林 裕介, 小林 裕明   子宮がんにおける摘出リンパ節を用いたOSNA法性能評価試験  

    日本婦人科腫瘍学会学術講演会プログラム・抄録集  2021.7  (公社)日本婦人科腫瘍学会

    　More details

    Language：Japanese  

  • 戸上 真一, 泉 明延, 徳留 明夫, 牛若 昂志, 福田 美香, 水野 美香, 簗詰 伸太郎, 神尾 真樹, 小林 裕明   婦人科がんセンチネルリンパ節生検　子宮がんセンチネルリンパ節生検　当科における診断治療の取り組み  

    日本癌治療学会学術集会抄録集  2021.10  (一社)日本癌治療学会

    　More details

    Language：English  

  • 萬浮 帆波, 牛若 昂志, 永田 真子, 黒田 高史, 水野 美香, 簗詰 伸太郎, 戸上 真一, 小林 裕明   卵巣腫瘍の良悪性鑑別のための腫瘍マーカーの組み合わせに関する検討  

    日本婦人科腫瘍学会学術講演会プログラム・抄録集  2021.7  (公社)日本婦人科腫瘍学会

    　More details

    Language：Japanese  

  • 戸上 真一, 牛若 昂志, 泉 明延, 徳留 明夫, 福田 美香, 水野 美香, 簗詰 伸太郎, 神尾 真樹, 小林 裕明   低侵襲手術時代における子宮体癌に対するリンパ節摘出の意義と方法　ダヴィンチXiシステムを用いた子宮体がん傍大動脈リンパ節郭清  

    日本内視鏡外科学会雑誌  2021.12  (一社)日本内視鏡外科学会

    　More details

    Language：Japanese  

  • 神尾 真樹, 徳留 明夫, 牛若 昂志, 福田 美香, 水野 美香, 簗詰 伸太郎, 戸上 真一, 小林 裕明   ロボット手術を安全に行うために　婦人科におけるセッティング  

    産婦人科手術  2022.6  (株)メジカルビュー社

    　More details

    Language：Japanese  

  • 簗詰 伸太郎, 牛若 昴志, 福田 美香, 泉 明延, 徳留 明夫, 水野 美香, 戸上 真一, 神尾 真樹, 小林 裕明   ロボット子宮体がん手術の進歩　高リスク体がん手術におけるデュアルドッキング手術の確立に向けて  

    日本産科婦人科内視鏡学会雑誌  2021.9  (一社)日本産科婦人科内視鏡学会

    　More details

    Language：Japanese  

  • Yanazume Shintaro, Ushiwaka Takashi, Yorouki Honami, Onigahara Motohisa, Fukuda Mika, Mizuno Mika, Togami Shinichi, Kamio Masaki, Kobayashi Hiroaki   Significance of zinc supplementation during chemotherapy for gynecological malignancy(和訳中)  

    日本産科婦人科学会雑誌  2022.2  (公社)日本産科婦人科学会

    　More details

    Language：English  

  • 簗詰 伸太郎, 牛若 昂志, 水野 美香, 戸上 真一, 小林 裕介, 古家 淳行, 赤羽 俊章, 北薗 育美, 谷本 昭英, 小林 裕明   POLE遺伝子異常を伴う子宮体癌における細胞学的特徴の検討  

    日本臨床細胞学会雑誌  2022.5  (公社)日本臨床細胞学会

    　More details

    Language：Japanese  

  • 中薗 麻衣, 水野 美香, 岩尾 葵, 齋藤 良介, 小林 裕介, 窪 凛太郎, 税所 篤志, 徳留 明夫, 福田 美香, 簗詰 伸太郎, 戸上 真一, 小林 裕明   高齢者に対するロボット手術のリスク評価  

    日本産科婦人科学会雑誌  2023.2  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 簗詰 伸太郎, 大塚 祥子, 岩尾 葵, 東 友梨子, 齋藤 良介, 徳留 明夫, 福田 美香, 水野 美香, 戸上 真一, 小林 裕明   進行・再発子宮体癌におけるペムブロリズマブとレンバチニブメシル酸塩併用療法の検討  

    日本産科婦人科学会雑誌  2023.2  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 弓指 里萌, 簗詰 伸太郎, 徳留 明夫, 齋藤 良介, 福田 美香, 水野 美香, 戸上 真一, 小林 裕明   絨毛癌再発にEP/EMA療法を含む集学的治療が著効した一例  

    日本産科婦人科学会雑誌  2023.2  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • Kamio Masaki, Ushiwaka Takashi, Yorouki Honami, Karakida Noriko, Uchida Natsuko, Sakihama Mika, Mizuno Mika, Yanazume Shintaro, Togami Shinichi, Kobayashi Hiroaki   子宮頸癌のスクリーニングにおける尿サンプルを用いたHPV検査の有用性評価(Evaluation of HPV test usefulness using urine sample as a screening for cervical cancer)  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：English  

  • Kamio Masaki, Ushiwaka Takashi, Yorouki Honami, Karakida Noriko, Uchida Natsuko, Sakihama Mika, Mizuno Mika, Yanazume Shintaro, Togami Shinichi, Kobayashi Hiroaki   子宮頸癌のスクリーニングにおける尿サンプルを用いたHPV検査の有用性評価(Evaluation of HPV test usefulness using urine sample as a screening for cervical cancer)  

    The Journal of Obstetrics and Gynaecology Research  2021.8  John Wiley & Sons Australia, Ltd

    　More details

    Language：English  

  • 水野 美香, 中薗 麻衣, 岩尾 葵, 齋藤 良介, 小林 裕介, 徳留 明夫, 福田 美香, 簗詰 伸太郎, 戸上 真一, 神尾 真樹, 小林 裕明   子宮体癌のロボット手術　肥満症例の周術期管理  

    日本産科婦人科学会雑誌  2023.2  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 小林 裕介, 北薗 育美, 赤羽 俊章, 簗詰 伸太郎, 田畑 和宏, 田崎 貴嗣, 水野 美香, 神尾 真樹, 戸上 真一, 小林 裕明, 谷本 昭英   子宮体癌のPOLE-mutation subtypeとNo Specific Molecular Profile subtype症例を鑑別する潜在的マーカーとしてのATM免疫組織化学染色(ATM Immunohistochemistry as a Potential Marker for the Differential Diagnosis of No Specific Molecular Profile and POLE-mutation Subtype Endometrioid Carcinoma)  

    日本婦人科腫瘍学会学術講演会プログラム・抄録集  2022.7  (公社)日本婦人科腫瘍学会

    　More details

    Language：English  

  • Yanazume Shintaro, Ushiwaka Takashi, Yorouki Honami, Onigahara Motohisa, Fukuda Mika, Mizuno Mika, Togami Shinichi, Kamio Masaki, Kobayashi Hiroaki   婦人科悪性腫瘍に対する化学療法中の亜鉛補給の意義(Significance of zinc supplementation during chemotherapy for gynecological malignancy)  

    日本産科婦人科学会雑誌  2022.2  (公社)日本産科婦人科学会

    　More details

    Language：English  

  • 大塚 祥子, 簗詰 伸太郎, 福田 美香, 徳留 明夫, 水野 美香, 戸上 真一, 小林 裕明   外科的閉経後の長期HRT施行後に転移性平滑筋腫を認めた一例  

    日本産科婦人科学会雑誌  2023.2  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • 小林 裕明, 戸上 真一, 簗詰 伸太郎, 水野 美香, 福田 美香, 齋藤 良介, 徳留 明夫   令和における子宮悪性腫瘍手術の低侵襲化とその課題　再発高リスク子宮体がんに対するロボット手術の試みと課題  

    日本癌治療学会学術集会抄録集  2022.10  (一社)日本癌治療学会

    　More details

    Language：English  

  • 牛若 昂志, 戸上 真一, 東 友梨子, 小林 裕介, 徳留 明夫, 福田 美香, 水野 美香, 簗詰 伸太郎, 神尾 真樹, 小林 裕明   ロボット支援傍大動脈リンパ節郭清時に遭遇した右腎動脈の破格のある1例  

    日本婦人科腫瘍学会学術講演会プログラム・抄録集  2022.7  (公社)日本婦人科腫瘍学会

    　More details

    Language：Japanese  

  • Yanazume Shintaro, Ushiwaka Takashi, Yorouki Honami, Onigahara Motohisa, Fukuda Mika, Mizuno Mika, Togami Shinichi, Kamio Masaki, Kobayashi Hiroaki   Significance of zinc supplementation during chemotherapy for gynecological malignancy(タイトル和訳中)  

    The Journal of Obstetrics and Gynaecology Research  2023.1  John Wiley & Sons Australia, Ltd

    　More details

    Language：English  

  • 簗詰 伸太郎, 牛若 昂志, 水野 美香, 戸上 真一, 小林 裕介, 小林 裕明   POLE遺伝子異常を伴う子宮体癌における細胞学的特徴の検討  

    日本婦人科腫瘍学会学術講演会プログラム・抄録集  2022.7  (公社)日本婦人科腫瘍学会

    　More details

    Language：Japanese  

  • 小林 裕介, 簗詰 伸太郎, 窪 凛太郎, 税所 篤志, 齋藤 良介, 徳留 明夫, 福田 美香, 水野 美香, 戸上 真一, 小林 裕明   ATM免疫染色はPOLE変異とNSMPサブタイプ子宮体がんを鑑別診断するための潜在的マーカーとなりうるか?  

    日本産科婦人科学会雑誌  2023.2  (公社)日本産科婦人科学会

    　More details

    Language：Japanese  

  • Kamio Masaki, Ushiwaka Takashi, Yorouki Honami, Karakida Noriko, Uchida Natsuko, Sakihama Mika, Mizuno Mika, Yanazume Shintaro, Togami Shinichi, Kobayashi Hiroaki   子宮頸癌のスクリーニングにおける尿サンプルを用いたHPV検査の有用性評価(Evaluation of HPV test usefulness using urine sample as a screening for cervical cancer)  

    The Journal of Obstetrics and Gynaecology Research  2021.8  John Wiley & Sons Australia, Ltd

    　More details

    Language：English  

  • Kamio Masaki, Ushiwaka Takashi, Yorouki Honami, Karakida Noriko, Uchida Natsuko, Sakihama Mika, Mizuno Mika, Yanazume Shintaro, Togami Shinichi, Kobayashi Hiroaki   子宮頸癌のスクリーニングにおける尿サンプルを用いたHPV検査の有用性評価(Evaluation of HPV test usefulness using urine sample as a screening for cervical cancer)  

    日本産科婦人科学会雑誌  2021.3  (公社)日本産科婦人科学会

    　More details

    Language：English  

  • Yanazume Shintaro, Ushiwaka Takashi, Yorouki Honami, Onigahara Motohisa, Fukuda Mika, Mizuno Mika, Togami Shinichi, Kamio Masaki, Kobayashi Hiroaki   婦人科悪性腫瘍に対する化学療法中の亜鉛補給の意義(Significance of zinc supplementation during chemotherapy for gynecological malignancy)  

    日本産科婦人科学会雑誌  2022.2  (公社)日本産科婦人科学会

    　More details

    Language：English  

▼display all